Avanos Medical (AVNS) 10-Q 5 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 01, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	HALYARD HEALTH, INC.
Entity Central Index Key	1,606,498
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		46,670,129

CONDENSED CONSOLIDATED INCOME S

CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net Sales	$ 400	$ 389.3	$ 784.8	$ 783.5
Cost of products sold	259.3	254.4	507.6	516.5
Gross Profit	140.7	134.9	277.2	267
Research and development	9.5	6.3	18.2	12.3
Selling and general expenses	107.9	105.8	200.7	203
Other expense and (income), net	5.7	0.7	7.6	(11.3)
Operating Profit	17.6	22.1	50.7	63
Interest income	0.1	0.1	0.3	0.2
Interest expense	(8.3)	(8.9)	(16.3)	(17.2)
Income Before Income Taxes	9.4	13.3	34.7	46
Income tax provision	(2.9)	(5.3)	(14)	(16.3)
Net Income	$ 6.5	$ 8	$ 20.7	$ 29.7
Per Share Basis
Basic (in dollars per share)	$ 0.14	$ 0.17	$ 0.44	$ 0.64
Diluted (in dollars per share)	$ 0.14	$ 0.17	$ 0.44	$ 0.63

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Net Income	$ 6.5	$ 8	$ 20.7	$ 29.7
Other Comprehensive (Loss) Income, Net of Tax
Unrealized currency translation adjustments	(2)	(3)	3.5	(9.8)
Defined benefit plans	0.1	0.2	0.1	0.2
Cash flow hedges	0.4	(0.5)	1.5	(0.2)
Total Other Comprehensive (Loss) Income, Net of Tax	(1.5)	(3.3)	5.1	(9.8)
Comprehensive Income	$ 5	$ 4.7	$ 25.8	$ 19.9

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 79.2	$ 129.5
Accounts receivable, net of allowances	195.2	224.7
Inventories	310.3	303.2
Prepaid expenses and other current assets	25	18.6
Total Current Assets	609.7	676
Property, Plant and Equipment, net	272.6	279.5
Goodwill	1,031.6	945.2
Other Intangible Assets, net	182.4	82.6
Deferred Tax Assets	12	14.9
Other Assets	3.7	2
TOTAL ASSETS	2,112	2,000.2
Current Liabilities
Trade accounts payable	168.6	163.2
Accrued expenses	136.3	152
Total Current Liabilities	304.9	315.2
Long-Term Debt	624	578.1
Deferred Tax Liabilities	63.4	23.8
Other Long-Term Liabilities	30.2	27.8
Total Liabilities	1,022.5	944.9
Commitments and Contingencies
Stockholders’ Equity
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued	0	0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,670,129 outstanding at June 30, 2016 and 46,614,947 outstanding at December 31, 2015	0.5	0.5
Additional paid-in capital	1,527.3	1,518
Accumulated deficit	(398.3)	(419)
Treasury stock	(1.9)	(1)
Accumulated other comprehensive loss	(38.1)	(43.2)
Total Stockholders’ Equity	1,089.5	1,055.3
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,112	$ 2,000.2

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares outstanding (in shares)	46,670,129	46,614,947

CONDENSED CONSOLIDATED CASH FLO

CONDENSED CONSOLIDATED CASH FLOW STATEMENTS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating Activities
Net income	$ 20.7	$ 29.7
Depreciation and amortization	31.8	32.3
Stock-based compensation expense	9.3	10.7
Net loss (gain) on asset dispositions	0.8	(9.8)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	4.8	33.6
Inventories	3.3	(40.9)
Prepaid expenses and other assets	3	2.7
Accounts payable	5.8	46.4
Accrued expenses	8.5	(49.2)
Other	6	0.2
Cash Provided by Operating Activities	94	55.7
Investing Activities
Capital expenditures	(14.1)	(45.2)
Acquisition of business, net of cash acquired	(175.1)	0
Proceeds from dispositions of property	0	7.7
Cash Used in Investing Activities	(189.2)	(37.5)
Financing Activities
Line of credit facility proceeds	72	0
Line of credit facility repayments	(27)	0
Debt repayments	0	(51)
Purchase of treasury stock	(0.9)	(1)
Proceeds from the exercise of stock options	0	0.9
Cash Provided by (Used in) Financing Activities	44.1	(51.1)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.8	(1.8)
(Decrease) Increase in Cash and Cash Equivalents	(50.3)	(34.7)
Cash and Cash Equivalents - Beginning of Period	129.5	149
Cash and Cash Equivalents - End of Period	$ 79.2	$ 114.3

Accounting Policies

Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies Background and Basis of Presentation Halyard Health, Inc. is a global business which seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. Our products and solutions are designed to address some of today’s most important healthcare needs, namely, preventing infections and reducing the use of narcotics while helping patients move from surgery to recovery. We market and support the efficacy, safety and economic benefit of our products with a significant body of clinical evidence. We operate in two business segments: Surgical and Infection Prevention (“S&IP”) and Medical Devices. References to “Halyard,” “Company,” “we,” “our” and “us” refer to Halyard Health, Inc. Interim Financial Statements We prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and the condensed consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2015 . Our unaudited interim condensed consolidated financial statements contain all material adjustments which are of a normal and recurring nature necessary to fairly state our financial condition, results of operations and cash flows for the periods presented. Use of Estimates Preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Estimates are used in accounting for, among other things, distributor rebate accruals, future cash flows associated with impairment testing for goodwill and long-lived assets, loss contingencies, deferred tax assets and potential income tax assessments. Actual results could differ from these estimates, and the effect of the change could be material to our financial statements. Changes in these estimates are recorded when known. New Accounting Standards In March 2016 , the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of accounting for share-based payment transactions including the accounting for income taxes, forfeitures, statutory tax withholding requirements and classification on the statement of cash flows. Under this ASU, all excess tax benefits or deficiencies are recognized as income tax expense or benefit in the income statement and the pool of windfall tax benefits as a component of additional paid-in capital is eliminated. In regards to forfeitures, companies may make a one-time policy election to use an estimated forfeiture rate or account for forfeitures as they occur. The policy election regarding forfeitures applies only to instruments with service conditions; the requirement to estimate the probability of achieving performance conditions remains. For statutory tax withholding requirements, this ASU allows for net settlement up to the employer’s maximum statutory tax withholding requirement. Formerly, only the minimum statutory tax withholding requirement was allowed to be met through net settlement while retaining equity classification. This ASU is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2016 . Earlier adoption is permitted in any interim or annual period for which financial statements have not yet been issued. The application of this ASU in regards to the accounting for income taxes, forfeitures and statutory tax withholding requirements should be applied using a modified retrospective application with a cumulative effect adjustment to additional paid-in capital as of the beginning of the period of adoption. The presentation of employee taxes paid on the statement of cash flows should be applied retrospectively. The adoption of this ASU is not expected to have a material effect on our financial position, results of operations or cash flows. In February 2016 , the FASB issued ASU No. 2016-02, Leases. This ASU requires the recognition of assets and liabilities for leases with lease terms of more than twelve months . The recognition, measurement and presentation of expenses and cash flows arising from a lease will depend primarily on its classification as a finance or an operating lease, with the classification criteria for distinguishing between the two being similar to the classification criteria for distinguishing between capital and operating leases under current GAAP. However, unlike current GAAP, recognition of finance and operating leases on the balance sheet is required, and additional disclosures are required to help financial statement users to better understand the amount, timing and uncertainty of cash flows arising from leases. This ASU requires modified retrospective application for existing leases. This ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 , however, earlier application is permitted. The impact of this ASU on our financial position, results of operations and cash flows are not yet known. In January 2016 , the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Liabilities. This ASU requires equity investments, except those accounted for under the equity method or those that result in consolidation of the equity investee, to be measured at fair value with changes in fair value recognized in net income. However, equity investments without readily determinable fair values may be measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments in the same issuer. In addition, this ASU provides for a qualitative impairment assessment for equity investments that do not have readily determinable fair values. This ASU also clarifies that entities should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. This ASU should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The provisions related to equity investments that do not have readily determinable fair values should be applied prospectively to such equity investments that exist as of the date of adoption. This ASU will be effective for fiscal years, and interim periods within those fiscal years beginning after December 15, 2017 . Early adoption of this ASU is permitted. The impact of this ASU on our financial position, results of operations and cash flows are not yet known. In May 2014 , the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers , which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. Subsequently, the FASB provided additional guidance regarding revenue recognition through the issuance of ASU No. 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations, and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. ASU 2016-08 requires an entity to determine whether the nature of its promise to customers is to provide the specified good or service itself (as a principal) or to arrange for that good or service to be provided by another party (as an agent). Notably, an entity is a principal if it controls the specified good or service prior to delivery of the specified good or service to the customer. Indicators of control include whether the entity is primarily responsible for fulfilling the promise to provide the specified good or service, whether the entity assumes inventory risk for the specified goods and whether the entity has discretion in establishing selling prices of the specified goods or services. ASU 2016-10 provides clarification on identifying performance obligations and the implementation of the licensing guidance. These ASUs are effective for public entities for annual and interim periods beginning after December 15, 2017 . Adoption prior to interim periods beginning after December 15, 2016 is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new ASU with restatement of prior years and one requiring prospective application of the new ASU with disclosure of results under old standards. During 2016 , we expect to complete an evaluation of the effects adoption of this ASU may have on our financial position, results of operations and cash flows.

Business Acquisition

Business Acquisition	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Acquisition	Business Acquisition On May 2, 2016 , Halyard acquired all of the issued and outstanding capital stock (the “Shares”) of Medsystems Holdings, Inc. (“Medsystems”) a Delaware corporation, for a purchase price of $175 million , net of cash acquired (the “Acquisition”). The Acquisition was funded with a combination of cash on hand and our Revolving Credit Facility (see Note 5 , “Debt”). Medsystems owns and conducts its primary business through CORPAK Medsystems (“Corpak”). Corpak’s innovative enteral access solutions and portfolio of nasogastric feeding tubes complements our existing enteral feeding products and creates a complete offering of enteral feeding solutions within our Medical Devices segment. In conjunction with the Acquisition, we identified intangible assets related to currently marketed products and in-process research and development (“IPR&D”) that we expect will yield economic benefits in the future. The identified intangible assets include technology, trademarks and customer relationships that were combined into composite intangible assets by product line in consideration of the following: • Our intent was to acquire the product portfolio and the related technology. • The trademarks will only be used to market the products associated with the existing technologies. Accordingly, their remaining economic lives are similar. • The customer base was considered, but was not identified as a separate intangible asset because the related cash flows are not separable from the related technology. • Low historical customer turnover rates supports longer lives for customer relationships which is consistent with the estimated remaining useful lives for the acquired technologies and trademarks. The fair value amounts have been determined using preliminary estimates. A preliminary valuation was completed in July 2016 and we believe it will be finalized by the end of 2016 . The preliminary allocation of the purchase price was as follows (in millions): Purchase Price Allocation Current assets acquired net of liabilities assumed $ 14.0 Property, plant and equipment 4.6 Identifiable intangible assets, excluding IPR&D 105.1 Identifiable IPR&D 5.7 Deferred tax liabilities (39.5 ) Goodwill 85.2 Total $ 175.1 Identifiable IPR&D includes a number of products that we expect to launch in 2017 . Goodwill arising from the Acquisition is not fully tax deductible. The identifiable intangible assets, excluding IPR&D, include the following (in millions): Fair Value Weighted Average Useful Lives (Yrs) Portfolio of disposables $ 102.9 15 Enteral access technology 2.2 6 Total $ 105.1 Corpak’s results have been included in the accompanying condensed consolidated income statement following the Acquisition on May 2, 2016 . Corpak’s revenue of $9 million is included in “Net Sales” in the accompanying condensed consolidated income statements for each of the three and six months ended June 30, 2016 . Due to the integration of Corpak’s portfolio of products into our existing digestive health products in the Medical Devices segment, earnings directly attributable to Corpak is not available. The following unaudited pro forma information is presented in the table below for the three and six months ended June 30, 2016 and 2015 as if the Acquisition had occurred on January 1, 2015 (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net sales $ 404.5 $ 402.6 $ 802.3 $ 809.5 Net income 8.9 8.6 21.6 28.5 Earnings per share: Basic $ 0.19 $ 0.18 $ 0.46 $ 0.61 Diluted 0.19 0.18 0.46 0.61 The pro forma financial information has been adjusted to include the effects of the Acquisition, including acquisition-related costs, amortization of acquired intangibles, incremental interest expense and related tax effects. The pro forma financial information is not necessarily indicative of the results of operations that would have been achieved had the Acquisition taken place as of January 1, 2015 . Upon Acquisition, we initiated activities to integrate the operations of Corpak into our company. These activities will include, but are not limited to, integration of corporate functions, information technology and alignment with our operations. In June 2016 , we initiated a restructuring plan to close the Medsystems corporate headquarters and operating facility in Buffalo Grove, Illinois and consolidate operations into our existing corporate and operational facilities by the third quarter of 2017 (the “Plan”). As of June 30, 2016, we have accrued $3 million for severance and benefits for employees impacted by the Plan. No cash payments for severance and benefits have been made through June 30, 2016 . For the three and six months ended June 30, 2016 , we have incurred $9 million and $10 million , respectively, for the acquisition, integration and restructuring activities described above, which are included in “Cost of products sold” and “Selling and general expenses” in the accompanying condensed consolidated income statements.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information Accounts Receivable Accounts receivable consist of the following (in millions): June 30, 2016 December 31, 2015 Accounts receivable $ 196.8 $ 226.3 Allowances and doubtful accounts (1.6 ) (1.6 ) Accounts receivable, net $ 195.2 $ 224.7 Inventories Inventories at the lower of cost (determined on the LIFO/FIFO or weighted-average cost methods) or market consist of the following (in millions): June 30, 2016 December 31, 2015 LIFO Non- Total LIFO Non- Total Raw materials $ 51.8 $ 0.8 $ 52.6 $ 49.7 $ 1.1 $ 50.8 Work in process 55.6 0.6 56.2 46.1 0.1 46.2 Finished goods 159.4 40.2 199.6 165.8 46.3 212.1 Supplies and other — 13.3 13.3 0.1 11.6 11.7 266.8 54.9 321.7 261.7 59.1 320.8 Excess of FIFO or weighted-average cost over LIFO cost (11.4 ) — (11.4 ) (17.6 ) — (17.6 ) Total $ 255.4 $ 54.9 $ 310.3 $ 244.1 $ 59.1 $ 303.2 Property, Plant and Equipment Property, plant and equipment consists of the following (in millions): June 30, 2016 December 31, 2015 Land $ 2.2 $ 2.1 Buildings 87.2 86.7 Machinery and equipment 503.1 492.8 Construction in progress 18.0 18.3 610.5 599.9 Less accumulated depreciation (337.9 ) (320.4 ) Total $ 272.6 $ 279.5 Depreciation expense was $11 million and $21 million for the three and six months ended June 30, 2016 , respectively, compared to $9 million and $19 million for the three and six months ended June 30, 2015 , respectively. Goodwill and Intangible Assets The changes in the carrying amount of goodwill by business segment are as follows (in millions): S&IP Medical Devices Consolidated Goodwill Accumulated Impairment Goodwill, net Goodwill Accumulated Impairment Goodwill, net Goodwill, net Balance at December 31, 2015 $ 740.8 $ (474.0 ) $ 266.8 $ 678.4 $ — $ 678.4 $ 945.2 Goodwill acquired — — — 85.2 — 85.2 85.2 Currency translation adjustment 0.2 — 0.2 1.0 — 1.0 1.2 Balance at June 30, 2016 $ 741.0 $ (474.0 ) $ 267.0 $ 764.6 $ — $ 764.6 $ 1,031.6 In connection with the Acquisition, we acquired $6 million of indefinite-lived intangible assets related to in-process research and development projects that we expect to launch in 2017 . Intangible assets subject to amortization consist of the following (in millions): June 30, 2016 December 31, 2015 Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Trademarks $ 126.5 $ (92.2 ) $ 34.3 $ 126.6 $ (90.3 ) $ 36.3 Patents and acquired technologies 253.9 (124.5 ) 129.4 149.1 (117.3 ) 31.8 Other 55.5 (42.5 ) 13.0 55.1 (40.6 ) 14.5 Total $ 435.9 $ (259.2 ) $ 176.7 $ 330.8 $ (248.2 ) $ 82.6 Amortization expense for intangible assets was $5 million and $11 million for the three and six months ended June 30, 2016 , respectively, compared to $6 million and $13 million for the three and six months ended June 30, 2015 , respectively. We estimate amortization expense for the remainder of 2016 and the following four years and beyond will be as follows (in millions): For the years ending December 31, 2016 $ 11.4 2017 21.4 2018 19.2 2019 15.4 2020 13.1 Thereafter 96.2 Total $ 176.7 Accrued Expenses Accrued expenses consist of the following (in millions): June 30, 2016 December 31, 2015 Accrued rebates $ 56.0 $ 73.9 Accrued salaries and wages 43.8 34.5 Accrued taxes - income and other 9.1 15.3 Other 27.4 28.3 Total $ 136.3 $ 152.0 Other Long-Term Liabilities Other long-term liabilities consist of the following (in millions): June 30, 2016 December 31, 2015 Taxes payable $ 3.0 $ 1.3 Accrued compensation benefits 9.8 9.5 Other 17.4 17.0 Total $ 30.2 $ 27.8

Fair Value Information

Fair Value Information	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Information	Fair Value Information The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are: Level 1—Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities. Level 2—Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3—Prices or valuations that require inputs that are significant to the valuation and are unobservable. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In the three and six months ended June 30, 2016 , there were no transfers among Level 1, 2 or 3 fair value determinations. The derivative liabilities for foreign exchange contracts were $1 million and $2 million as of June 30, 2016 and December 31, 2015 , respectively and are included in the condensed consolidated balance sheet in accrued expenses. The derivative assets for foreign exchange contracts as of June 30, 2016 were $1 million . Derivative assets for foreign exchange contracts were not significant as of December 31, 2015 . These derivatives are classified as Level 2 of the fair value hierarchy. The fair values of derivatives used to manage foreign currency risk is based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. The following table includes the fair value of our financial instruments for which disclosure of fair value is required (in millions): June 30, 2016 December 31, 2015 Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Assets Cash and cash equivalents 1 $ 79.2 $ 79.2 $ 129.5 $ 129.5 Liabilities Senior Unsecured Notes, net of Unamortized Discount 1 246.2 244.1 245.9 252.5 Senior Secured Term Loan, net of Unamortized Discount 2 332.8 339.2 332.2 337.3 Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature. The fair value of the Senior Unsecured Notes was based on observable quoted prices on an active primary exchange. The fair value of our Senior Secured Term Loan was based on observable quoted prices in a secondary market.

Debt

Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt	Debt As of June 30, 2016 and December 31, 2015 , our debt balances were as follows (in millions): Weighted-Average Interest Rate Maturities June 30, 2016 December 31, 2015 Revolving Credit Facility 2.74 % 2019 $ 45.0 $ — Senior Secured Term Loan 4.00 % 2021 339.0 339.0 Senior Unsecured Notes 6.25 % 2022 250.0 250.0 Unamortized Debt Discounts and Issuance Costs: Senior Secured Term Loan (6.2 ) (6.8 ) Senior Unsecured Notes (3.8 ) (4.1 ) Total Debt $ 624.0 $ 578.1 Senior Secured Term Loan and Revolving Credit Facility The senior secured term loan (the “Term Loan Facility”) is under a credit agreement that includes a five -year senior secured revolving credit facility allowing borrowings of up to $250 million , with a letter of credit sub-facility in an amount of $75 million and a swingline sub-facility in an amount of $25 million (the “Revolving Credit Facility”, and together with the Term Loan Facility, the “Senior Credit Facilities”). The Senior Credit Facilities are secured by substantially all of our assets located in the United States and a certain percentage of our foreign subsidiaries’ capital stock. Borrowings under the Term Loan Facility bear interest, at our option, at either (i) a reserve-adjusted LIBOR rate, subject to a floor of 0.75% , plus 3.25% , or (ii) a base rate, subject to a floor of 0.75% , (calculated as the greatest of (1) the prime rate, (2) the U.S. federal funds effective rate plus 0.50% or (3) the one month LIBOR rate plus 1.00% ) plus 2.25% . As of June 30, 2016 , the interest rate in effect for the Term Loan Facility was 4.00% . Borrowings under the Revolving Credit Facility bear interest, at our option, at either (i) a reserve-adjusted LIBOR rate, plus a margin ranging between 1.75% to 2.50% per annum, depending on our consolidated total leverage ratio, or (ii) the base rate plus a margin ranging between 0.75% to 1.50% per annum, depending on our consolidated total leverage ratio. The unused portion of the Revolving Credit Facility is subject to a commitment fee equal to (i) 0.25% per annum, when our consolidated total leverage ratio is less than 2.25 to 1.00 or (ii) 0.40% per annum, otherwise. As of June 30, 2016 , we had $45 million of borrowings and letters of credit of $3 million outstanding under the Revolving Credit Facility, leaving $202 million available for borrowing. On May 2, 2016 , we borrowed $72 million under our Revolving Credit Facility to partially fund our acquisition of Medsystems. See Note 2 , “Business Acquisition” for a description of this acquisition. By June 30, 2016 , we had repaid $27 million of the borrowings on our Revolving Credit Facility. As of June 30, 2016 , the interest rate in effect for the Revolving Credit Facility was 2.72% . Senior Unsecured Notes The senior unsecured notes (the “Notes”) will mature on October 15, 2022 and interest accrues at a rate of 6.25% per annum and is payable semi-annually in arrears on April 15 and October 15 of each year.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income The changes in the components of Accumulated Other Comprehensive Income (“AOCI”), net of tax, are as follows (in millions): Unrealized Translation Cash Flow Hedges Defined Benefit Pension Plans Accumulated Other Comprehensive Income Balance, December 31, 2015 $ (40.4 ) $ (1.2 ) $ (1.6 ) $ (43.2 ) Other comprehensive income 3.5 1.5 0.1 5.1 Balance, June 30, 2016 $ (36.9 ) $ 0.3 $ (1.5 ) $ (38.1 ) The changes in the components of AOCI, including the tax effect, are as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Unrealized translation $ (2.0 ) $ (3.0 ) $ 3.5 $ (9.8 ) Defined benefit pension plans 0.1 0.1 0.1 0.1 Tax effect — 0.1 — 0.1 Defined benefit pension plans, net of tax 0.1 0.2 0.1 0.2 Cash flow hedges 0.4 (0.8 ) 1.9 (0.3 ) Tax effect — 0.3 (0.4 ) 0.1 Cash flow hedges, net of tax 0.4 (0.5 ) 1.5 (0.2 ) Change in AOCI $ (1.5 ) $ (3.3 ) $ 5.1 $ (9.8 )

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Aggregate stock-based compensation expense for the three and six months ended June 30, 2016 was $6 million and $9 million , respectively, compared to $6 million and $11 million , respectively, for the three and six months ended June 30, 2015 . Stock-based compensation expense related to stock options was $2 million and $3 million , respectively for the three and six months ended June 30, 2016 compared to $3 million and $4 million , respectively for the three and six months ended June 30, 2015 . Stock-based compensation expense related to restricted share units was $1 million and $4 million , respectively, for the three and six months ended June 30, 2016 compared to $3 million and $7 million , respectively, for the three and six months ended June 30, 2015 . In the six months ended June 30, 2016 , we issued approximately 230,000 restricted share units for which vesting is conditioned on meeting a defined measure of total shareholder return (“TSR units”) over a restricted period of three years . Total shareholder return is measured as our stock price performance over the restricted period compared to a defined group of peer companies. The expense recognition for TSR units differs from awards with service and performance conditions in that the expense is recognized over the restricted period regardless of whether the total shareholder return target is met or not, while expense for awards with service and performance conditions is recognized based on the number of awards expected to vest. The fair value of restricted share units with a TSR vesting condition is determined using a Monte Carlo simulation which incorporates a volatility assumption based on the average stock price volatility for a peer group of companies over a period of three years, which matches the restricted period. For the awards granted in the three and six months ended June 30, 2016 , the assumed volatility was 25% and the weighted average fair value per TSR unit was $38.64 . In the three and six months ended June 30, 2016 , stock-based compensation expense related to TSR units was $2 million and $2 million , respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are subject to various legal proceedings, claims and governmental inspections, audits or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, employment and other matters, including the matters described below. Under the terms of the distribution agreement we entered into with Kimberly-Clark Corporation (“Kimberly-Clark”) prior to our spin-off, legal proceedings, claims and other liabilities that are primarily related to our business are our responsibility and we are obligated to indemnify and hold Kimberly-Clark harmless for such matters (“Indemnification Obligation”). For the three and six months ended June 30, 2016 , we have incurred $6 million and $10 million , respectively, for such matters. Amounts incurred related to these matters in the comparable prior year periods were not material. The only exception to the Indemnification Obligation relates to the pain pump litigation referenced in this paragraph. We are one of several manufacturers of continuous infusion medical devices, such as our ON-Q PAINBUSTER pain pumps, that are involved in several different pending or threatened litigation matters from multiple plaintiffs alleging that use of the continuous infusion device to deliver anesthetics directly into a synovial joint after surgery resulted in postarthroscopic glenohumeral chondrolysis, or a disintegration of the cartilage covering the bones in the joint (typically, in the shoulder). Plaintiffs generally seek monetary damages and attorneys’ fees. While Kimberly-Clark is retaining the liabilities related to these matters, the distribution agreement between us and Kimberly-Clark provides that we will indemnify Kimberly-Clark for any such claims or causes of actions arising after the spin-off. We have an Indemnification Obligation for, and have assumed the defense of, the matter styled Bahamas Surgery Center, LLC v. Kimberly-Clark Corporation and Halyard Health, Inc., f/k/a Prime Healthcare Centinela, LLC, et al. v. Kimberly-Clark Corporation, et al., No. 2:14-cv-08390-DMG-SH (C.D. Cal.), filed on October 29, 2014. In that case, the plaintiff brings a putative class action asserting claims for common law fraud (affirmative misrepresentation and fraudulent concealment) and violation of California’s Unfair Competition Law in connection with our marketing and sale of MicroCool surgical gowns. On March 21, 2016, we moved to dismiss the non-California plaintiffs, and on May 26, 2016, the court issued an order dismissing them. On June 14, 2016, the court granted the plaintiffs’ unopposed motion to dismiss Prime Healthcare Centinela, LLC and one of the other two remaining California plaintiffs, leaving only the current named plaintiff, Bahamas Surgery Center, LLC. On June 1, 2016, the plaintiff moved for class certification of a California-only damages class and a California-only injunctive relief class. Although the plaintiff did not also move for certification of a nationwide class to determine liability, damages, or injunctive relief, it did move for certification of a nationwide “issue” class purporting to resolve certain issues allegedly “common” to members of that class. On July 8, 2016, we moved for summary judgment. The parties also remain engaged in discovery. We intend to continue our vigorous defense of the matter. In June 2015, we were served with a subpoena from the Department of Veterans Affairs Office of the Inspector General (“VA OIG”) seeking information related to the design, manufacture, testing, sale and promotion of MicroCool and other Company surgical gowns, and, in July 2015, we also became aware that the subpoena and an earlier VA OIG subpoena served on Kimberly-Clark requesting information about gown sales to the federal government are related to a United States Department of Justice (“DOJ”) investigation. In May 2016, we were also served with a subpoena from the Department of Justice seeking further information related to Company gowns. We could be subject to litigation relating to this investigation, by either governmental agencies or private parties. If a claim is asserted against Kimberly-Clark relating to MicroCool gowns or other Company surgical gowns, we expect that such a claim would give rise to an Indemnification Obligation under the distribution agreement with Kimberly-Clark. The Company is cooperating with the VA OIG’s request and the DOJ investigation. We have been served with a complaint in a matter styled Jackson v. Halyard Health, Inc., Robert E. Abernathy, Steven E. Voskuil, et al., No. 1:16-cv-05093-LTS (S.D.N.Y.), filed on June 28, 2016. In that case, the plaintiff brings a putative class action against the Company, our Chief Executive Officer, our Chief Financial Officer and other defendants, asserting claims for violations of the Securities Exchange Act, Sections 10(b) and 20(a). The plaintiff alleges that the defendants made misrepresentations and failed to disclose certain information about the safety and effectiveness of our MicroCool gowns and thereby artificially inflated the Company’s stock prices during the respective class periods. The alleged class period for purchasers of Kimberly-Clark securities who subsequently received Halyard Health securities is February 25, 2013 to October 21, 2014, and the alleged class period for purchasers of Halyard Health securities is October 21, 2014 to April 29, 2016. We intend to vigorously defend this matter. We operate in an industry characterized by extensive patent litigation and competitors may claim that our products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require us to make significant royalty payments in order to continue selling the affected products. At any given time we may be involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time. We maintain general and professional liability, product liability and other insurance in an amount that we believe is reasonably adequate to insulate us from material liability for claims. However, our insurance policies may not cover all of these matters and may not fully cover liabilities arising out of these matters. In addition, we may be obligated to indemnify our directors and officers against these matters. Although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, individually or in the aggregate, on our financial condition, results of operations or liquidity. However the above matters, regardless of the outcome, could disrupt our business and result in substantial costs and diversion of management attention. We are subject to federal, state and local environmental protection laws and regulations with respect to our business operations and are operating in compliance with, or taking action aimed at ensuring compliance with, these laws and regulations. None of our compliance obligations with environmental protection laws and regulations, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition, results of operations or liquidity.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments The derivative liabilities for foreign exchange contracts as of June 30, 2016 and December 31, 2015 were $1 million and $2 million , respectively, and are included in the condensed consolidated balance sheet in accrued expenses. The derivative assets for foreign exchange contracts as of June 30, 2016 were $1 million . Derivative assets for foreign exchange contracts were not significant as of December 31, 2015 . For derivative instruments that are designated and qualify as cash flow hedges, gains or losses recognized to earnings were not significant in the three and six months ended June 30, 2016 and 2015 . As of June 30, 2016 , the aggregate notional values of outstanding foreign exchange derivative contracts designated as cash flow hedges were $36 million . Cash flow hedges resulted in no significant ineffectiveness in the three and six months ended June 30, 2016 and 2015 . For the three and six months ended June 30, 2016 and 2015 , no gains or losses were reclassified into earnings as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At June 30, 2016 , amounts to be reclassified from AOCI during the next twelve months are not expected to be significant. The maximum maturity of cash flow hedges in place at June 30, 2016 is June 2017 . Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in other income and expense, net. These gains or losses have not been significant for the three and six months ended June 30, 2016 and 2015 . The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. As of June 30, 2016 , the notional amount of these undesignated derivative instruments was $4 million .

Earnings Per Share ("EPS")

Earnings Per Share ("EPS")	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”) Basic EPS is calculated by dividing net income by the weighted average number of common shares outstanding during each period. Diluted earnings per share is calculated by dividing net income by the weighted average number of common shares outstanding and the effect of all dilutive common stock equivalents outstanding during each period, as determined using the treasury stock method. The calculation of basic and diluted earnings per share for the three and six months ended June 30, 2016 and 2015 is set forth in the following table (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net income $ 6.5 $ 8.0 $ 20.7 $ 29.7 Weighted Average Shares Outstanding: Basic weighted average shares outstanding 46.7 46.6 46.6 46.6 Dilutive effect of stock options and restricted share unit awards 0.2 0.2 0.2 0.2 Diluted weighted average shares outstanding 46.9 46.8 46.8 46.8 Earnings Per Share Basic $ 0.14 $ 0.17 $ 0.44 $ 0.64 Diluted $ 0.14 $ 0.17 $ 0.44 $ 0.63 For each of the three and six months ended June 30, 2016 , 1.9 million of potentially dilutive stock options and restricted share units were excluded from the computation of earnings per share as their effect would have been anti-dilutive.

Business Segment Information

Business Segment Information	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information Information concerning unaudited consolidated operations by business segment is presented in the following table (in millions): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net Sales S&IP $ 256.7 $ 255.3 $ 511.4 $ 510.1 Medical Devices 141.5 126.9 268.2 249.2 Corporate and Other 1.8 7.1 5.2 24.2 Total Net Sales 400.0 389.3 784.8 783.5 Operating Profit S&IP 25.1 25.5 49.7 45.0 Medical Devices 29.0 33.3 58.7 58.1 Corporate and Other (a) (30.8 ) (36.0 ) (50.1 ) (51.4 ) Other (expense) and income, net (b) (5.7 ) (0.7 ) (7.6 ) 11.3 Total Operating Profit 17.6 22.1 50.7 63.0 Interest income 0.1 0.1 0.3 0.2 Interest expense (8.3 ) (8.9 ) (16.3 ) (17.2 ) Income before Income Taxes $ 9.4 $ 13.3 $ 34.7 $ 46.0 ______________________________ (a) Corporate and Other for the three and six months ended June 30, 2016 includes $17 million and $32 million , respectively, of general expenses, $2 million and $5 million , respectively, of post spin-related transition expenses, $9 million and $10 million , respectively, of acquisition, integration and restructuring expenses related to the Acquisition (See Note 2 , “Business Acquisition”) and $2 million and $3 million , respectively of costs related to corporate sales. Corporate and Other for the three and six months ended June 30, 2015 includes $13 million and $22 million , respectively, of general expenses and $20 million and $30 million , respectively, of post spin-related transition expenses and $4 million of costs and $2 million of profit, respectively, from corporate sales. (b) Other expense includes amounts incurred related to litigation matters. See Note 8 , “Commitments and Contingencies.”

Supplemental Guarantor Financia

Supplemental Guarantor Financial Information	6 Months Ended
	Jun. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Supplemental Guarantor Financial Information	Supplemental Guarantor Financial Information The Notes (described in Note 5 , “Debt”) are guaranteed, jointly and severally by each of our domestic subsidiaries that guarantees the Senior Credit Facilities (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions as defined in the Indenture dated October 17, 2014 . Each Guarantor Subsidiary is directly or indirectly 100% -owned by Halyard Health, Inc. Each of the guarantees of the Notes is a general unsecured obligation of each Guarantor Subsidiary and ranks equally in right of payment with all existing and future indebtedness and all other obligations (except subordinated indebtedness) of each Guarantor Subsidiary. The following condensed consolidating balance sheets as of June 30, 2016 and December 31, 2015 and the condensed statements of income for the three and six months ended June 30, 2016 and 2015 and cash flows for the six months ended June 30, 2016 and 2015 provide condensed consolidating financial information for Halyard Health, Inc. (“Parent”), the Guarantor Subsidiaries on a combined basis, the non-guarantor subsidiaries on a combined basis and the Parent and its subsidiaries on a consolidated basis. The following condensed consolidating financial information contains preliminary purchase accounting allocations. The Parent and the Guarantor Subsidiaries use the equity method of accounting to reflect ownership interests in subsidiaries that are eliminated upon consolidation. Eliminating entries in the following condensed consolidating financial information represent adjustments to (i) eliminate intercompany transactions between or among the Parent, the Guarantor Subsidiaries and the non-guarantor subsidiaries and (ii) eliminate the investments in subsidiaries. HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Three Months Ended June 30, 2016 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 372.3 $ 110.8 $ (83.1 ) $ 400.0 Cost of products sold — 247.7 94.7 (83.1 ) 259.3 Gross Profit — 124.6 16.1 — 140.7 Research and development — 9.5 — — 9.5 Selling and general expenses 11.1 81.5 15.3 — 107.9 Other (income) and expense, net (0.3 ) 12.1 (6.1 ) — 5.7 Operating (Loss) Profit (10.8 ) 21.5 6.9 — 17.6 Interest income 0.1 — 0.7 (0.7 ) 0.1 Interest expense (8.4 ) (0.6 ) — 0.7 (8.3 ) (Loss) Income Before Income Taxes (19.1 ) 20.9 7.6 — 9.4 Income tax benefit (provision) 7.2 (8.7 ) (1.4 ) — (2.9 ) Equity in earnings of consolidated subsidiaries 18.4 7.7 — (26.1 ) — Net Income 6.5 19.9 6.2 (26.1 ) 6.5 Total other comprehensive loss, net of tax (1.5 ) (0.5 ) (2.9 ) 3.4 (1.5 ) Comprehensive Income $ 5.0 $ 19.4 $ 3.3 $ (22.7 ) $ 5.0 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Three Months Ended June 30, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 364.6 $ 113.5 $ (88.8 ) $ 389.3 Cost of products sold — 247.0 96.2 (88.8 ) 254.4 Gross Profit — 117.6 17.3 — 134.9 Research and development — 6.3 — — 6.3 Selling and general expenses 9.1 81.1 15.6 — 105.8 Other (income) and expense, net (0.2 ) 2.5 (1.6 ) — 0.7 Operating (Loss) Profit (8.9 ) 27.7 3.3 — 22.1 Interest income 0.3 — 1.7 (1.9 ) 0.1 Interest expense (10.0 ) (0.7 ) (0.1 ) 1.9 (8.9 ) (Loss) Income Before Income Taxes (18.6 ) 27.0 4.9 — 13.3 Income tax benefit (provision) 13.4 (18.7 ) — — (5.3 ) Equity in earnings of consolidated subsidiaries 13.2 2.9 — (16.1 ) — Net Income 8.0 11.2 4.9 (16.1 ) 8.0 Total other comprehensive loss, net of tax — (0.2 ) (3.1 ) — (3.3 ) Comprehensive Income $ 8.0 $ 11.0 $ 1.8 $ (16.1 ) $ 4.7 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Six Months Ended June 30, 2016 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 723.5 $ 213.6 $ (152.3 ) $ 784.8 Cost of products sold — 479.9 180.0 (152.3 ) 507.6 Gross Profit — 243.6 33.6 — 277.2 Research and development — 18.2 — — 18.2 Selling and general expenses 20.7 150.8 29.2 — 200.7 Other (income) and expense, net (0.4 ) 20.0 (12.0 ) — 7.6 Operating (Loss) Profit (20.3 ) 54.6 16.4 — 50.7 Interest income 0.2 — 1.3 (1.2 ) 0.3 Interest expense (16.5 ) (1.0 ) — 1.2 (16.3 ) (Loss) Income Before Income Taxes (36.6 ) 53.6 17.7 — 34.7 Income tax benefit (provision) 13.8 (20.0 ) (7.8 ) — (14.0 ) Equity in earnings of consolidated subsidiaries 43.5 12.4 — (55.9 ) — Net Income 20.7 46.0 9.9 (55.9 ) 20.7 Total other comprehensive income, net of tax 5.1 4.5 2.7 (7.2 ) 5.1 Comprehensive Income $ 25.8 $ 50.5 $ 12.6 $ (63.1 ) $ 25.8 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Six Months Ended June 30, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 724.9 $ 227.2 $ (168.6 ) $ 783.5 Cost of products sold — 490.6 194.5 (168.6 ) 516.5 Gross Profit — 234.3 32.7 — 267.0 Research and development — 12.3 — — 12.3 Selling and general expenses 18.2 154.3 30.5 — 203.0 Other (income) and expense, net (0.4 ) 4.8 (15.7 ) — (11.3 ) Operating (Loss) Profit (17.8 ) 62.9 17.9 — 63.0 Interest income 0.3 — 1.8 (1.9 ) 0.2 Interest expense (17.8 ) (1.0 ) (0.3 ) 1.9 (17.2 ) (Loss) Income Before Income Taxes (35.3 ) 61.9 19.4 — 46.0 Income tax benefit (provision) 13.4 (24.2 ) (5.5 ) — (16.3 ) Equity in earnings of consolidated subsidiaries 51.6 16.1 — (67.7 ) — Net Income 29.7 53.8 13.9 (67.7 ) 29.7 Total other comprehensive loss, net of tax — (0.3 ) (9.5 ) — (9.8 ) Comprehensive Income $ 29.7 $ 53.5 $ 4.4 $ (67.7 ) $ 19.9 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions) As of June 30, 2016 Parent Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current Assets Cash and cash equivalents $ 16.6 $ 9.3 $ 53.3 $ — $ 79.2 Accounts receivable, net 3.4 490.9 223.7 (522.8 ) 195.2 Inventories — 273.1 37.2 — 310.3 Prepaid and other current assets 5.5 17.4 2.8 (0.7 ) 25.0 Total Current Assets 25.5 790.7 317.0 (523.5 ) 609.7 Property, Plant and Equipment, net — 225.3 47.3 — 272.6 Investment in Consolidated Subsidiaries 2,032.1 285.5 — (2,317.6 ) — Goodwill — 1,003.7 27.9 — 1,031.6 Other Intangible Assets, net — 182.4 — — 182.4 Other Assets 1.2 2.4 12.1 — 15.7 TOTAL ASSETS $ 2,058.8 $ 2,490.0 $ 404.3 $ (2,841.1 ) $ 2,112.0 LIABILITIES AND EQUITY Current Liabilities Trade accounts payable $ 335.1 $ 311.2 $ 41.0 $ (518.7 ) $ 168.6 Accrued expenses 8.4 106.2 26.4 (4.7 ) 136.3 Total Current Liabilities 343.5 417.4 67.4 (523.4 ) 304.9 Long-Term Debt 624.0 — — — 624.0 Other Long-Term Liabilities 1.8 83.7 8.1 — 93.6 Total Liabilities 969.3 501.1 75.5 (523.4 ) 1,022.5 Total Equity 1,089.5 1,988.9 328.8 (2,317.7 ) 1,089.5 TOTAL LIABILITIES AND EQUITY $ 2,058.8 $ 2,490.0 $ 404.3 $ (2,841.1 ) $ 2,112.0 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions) As of December 31, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Current Assets Cash and cash equivalents $ 92.3 $ — $ 39.7 $ (2.5 ) $ 129.5 Accounts receivable, net 3.0 440.8 221.7 (440.8 ) 224.7 Inventories — 258.4 44.8 — 303.2 Prepaid and other current assets 5.0 10.8 3.0 (0.2 ) 18.6 Total Current Assets 100.3 710.0 309.2 (443.5 ) 676.0 Property, Plant and Equipment, net — 228.7 50.8 — 279.5 Investment in Consolidated Subsidiaries 1,750.8 277.7 — (2,028.5 ) — Goodwill — 918.6 26.6 — 945.2 Other Intangible Assets, net — 82.6 — — 82.6 Other Assets 1.4 0.3 15.2 — 16.9 TOTAL ASSETS $ 1,852.5 $ 2,217.9 $ 401.8 $ (2,472.0 ) $ 2,000.2 LIABILITIES AND EQUITY Current Liabilities Trade accounts payable $ 251.4 $ 309.4 $ 42.7 $ (440.3 ) $ 163.2 Accrued expenses 6.6 115.4 33.4 (3.4 ) 152.0 Total Current Liabilities 258.0 424.8 76.1 (443.7 ) 315.2 Long-Term Debt 578.1 — — — 578.1 Other Long-Term Liabilities 1.8 41.6 8.2 — 51.6 Total Liabilities 837.9 466.4 84.3 (443.7 ) 944.9 Total Equity 1,014.6 1,751.5 317.5 (2,028.3 ) 1,055.3 TOTAL LIABILITIES AND EQUITY $ 1,852.5 $ 2,217.9 $ 401.8 $ (2,472.0 ) $ 2,000.2 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions) Six Months Ended June 30, 2016 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Cash (Used in) Provided by Operating Activities $ (7.5 ) $ 85.5 $ 16.0 $ — $ 94.0 Investing Activities Capital expenditures — (11.6 ) (2.5 ) — (14.1 ) Acquisition of business, net of cash acquired (175.1 ) — — — (175.1 ) Intercompany contributions 0.5 (65.0 ) 1.8 62.7 — Cash Used in Investing Activities (174.6 ) (76.6 ) (0.7 ) 62.7 (189.2 ) Financing Activities Intercompany contributions 62.3 — (2.1 ) (60.2 ) — Line of credit facility proceeds 72.0 — — — 72.0 Line of credit facility repayments (27.0 ) — — — (27.0 ) Purchase of treasury stock (0.9 ) — — — (0.9 ) Cash Provided by (Used in) Financing Activities 106.4 — (2.1 ) (60.2 ) 44.1 Effect of Exchange Rate on Cash and Cash Equivalents — 0.4 0.4 — 0.8 (Decrease) Increase in Cash and Cash Equivalents (75.7 ) 9.3 13.6 2.5 (50.3 ) Cash and Cash Equivalents, Beginning of Period 92.3 — 39.7 (2.5 ) 129.5 Cash and Cash Equivalents, End of Period $ 16.6 $ 9.3 $ 53.3 $ — $ 79.2 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions) Six Months Ended June 30, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Cash (Used in) Provided by Operating Activities $ (18.9 ) $ 22.4 $ 52.2 $ — $ 55.7 Investing Activities Capital expenditures — (39.1 ) (6.1 ) — (45.2 ) Proceeds from property dispositions — — 7.7 — 7.7 Cash (Used in) Provided by Investing Activities — (39.1 ) 1.6 — (37.5 ) Financing Activities Intercompany contributions 62.4 13.2 (75.6 ) — — Debt repayments (51.0 ) — — — (51.0 ) Purchase of treasury stock (1.0 ) — — — (1.0 ) Proceeds from the exercise of stock options 0.9 — — — 0.9 Cash Provided by (Used in) Financing Activities 11.3 13.2 (75.6 ) — (51.1 ) Effect of Exchange Rate on Cash and Cash Equivalents — (0.1 ) (1.7 ) — (1.8 ) Decrease in Cash and Cash Equivalents (7.6 ) (3.6 ) (23.5 ) — (34.7 ) Cash and Cash Equivalents, Beginning of Period 101.2 3.9 43.9 — 149.0 Cash and Cash Equivalents, End of Period $ 93.6 $ 0.3 $ 20.4 $ — $ 114.3

Accounting Policies (Policies)

Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Background and Basis of Presentation	Background and Basis of Presentation Halyard Health, Inc. is a global business which seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. Our products and solutions are designed to address some of today’s most important healthcare needs, namely, preventing infections and reducing the use of narcotics while helping patients move from surgery to recovery. We market and support the efficacy, safety and economic benefit of our products with a significant body of clinical evidence. We operate in two business segments: Surgical and Infection Prevention (“S&IP”) and Medical Devices. References to “Halyard,” “Company,” “we,” “our” and “us” refer to Halyard Health, Inc. Interim Financial Statements We prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and the condensed consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2015 . Our unaudited interim condensed consolidated financial statements contain all material adjustments which are of a normal and recurring nature necessary to fairly state our financial condition, results of operations and cash flows for the periods presented.
Use of Estimates	Use of Estimates Preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Estimates are used in accounting for, among other things, distributor rebate accruals, future cash flows associated with impairment testing for goodwill and long-lived assets, loss contingencies, deferred tax assets and potential income tax assessments. Actual results could differ from these estimates, and the effect of the change could be material to our financial statements. Changes in these estimates are recorded when known.
New Accounting Standards	New Accounting Standards In March 2016 , the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of accounting for share-based payment transactions including the accounting for income taxes, forfeitures, statutory tax withholding requirements and classification on the statement of cash flows. Under this ASU, all excess tax benefits or deficiencies are recognized as income tax expense or benefit in the income statement and the pool of windfall tax benefits as a component of additional paid-in capital is eliminated. In regards to forfeitures, companies may make a one-time policy election to use an estimated forfeiture rate or account for forfeitures as they occur. The policy election regarding forfeitures applies only to instruments with service conditions; the requirement to estimate the probability of achieving performance conditions remains. For statutory tax withholding requirements, this ASU allows for net settlement up to the employer’s maximum statutory tax withholding requirement. Formerly, only the minimum statutory tax withholding requirement was allowed to be met through net settlement while retaining equity classification. This ASU is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2016 . Earlier adoption is permitted in any interim or annual period for which financial statements have not yet been issued. The application of this ASU in regards to the accounting for income taxes, forfeitures and statutory tax withholding requirements should be applied using a modified retrospective application with a cumulative effect adjustment to additional paid-in capital as of the beginning of the period of adoption. The presentation of employee taxes paid on the statement of cash flows should be applied retrospectively. The adoption of this ASU is not expected to have a material effect on our financial position, results of operations or cash flows. In February 2016 , the FASB issued ASU No. 2016-02, Leases. This ASU requires the recognition of assets and liabilities for leases with lease terms of more than twelve months . The recognition, measurement and presentation of expenses and cash flows arising from a lease will depend primarily on its classification as a finance or an operating lease, with the classification criteria for distinguishing between the two being similar to the classification criteria for distinguishing between capital and operating leases under current GAAP. However, unlike current GAAP, recognition of finance and operating leases on the balance sheet is required, and additional disclosures are required to help financial statement users to better understand the amount, timing and uncertainty of cash flows arising from leases. This ASU requires modified retrospective application for existing leases. This ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 , however, earlier application is permitted. The impact of this ASU on our financial position, results of operations and cash flows are not yet known. In January 2016 , the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Liabilities. This ASU requires equity investments, except those accounted for under the equity method or those that result in consolidation of the equity investee, to be measured at fair value with changes in fair value recognized in net income. However, equity investments without readily determinable fair values may be measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments in the same issuer. In addition, this ASU provides for a qualitative impairment assessment for equity investments that do not have readily determinable fair values. This ASU also clarifies that entities should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. This ASU should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The provisions related to equity investments that do not have readily determinable fair values should be applied prospectively to such equity investments that exist as of the date of adoption. This ASU will be effective for fiscal years, and interim periods within those fiscal years beginning after December 15, 2017 . Early adoption of this ASU is permitted. The impact of this ASU on our financial position, results of operations and cash flows are not yet known. In May 2014 , the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers , which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. Subsequently, the FASB provided additional guidance regarding revenue recognition through the issuance of ASU No. 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations, and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. ASU 2016-08 requires an entity to determine whether the nature of its promise to customers is to provide the specified good or service itself (as a principal) or to arrange for that good or service to be provided by another party (as an agent). Notably, an entity is a principal if it controls the specified good or service prior to delivery of the specified good or service to the customer. Indicators of control include whether the entity is primarily responsible for fulfilling the promise to provide the specified good or service, whether the entity assumes inventory risk for the specified goods and whether the entity has discretion in establishing selling prices of the specified goods or services. ASU 2016-10 provides clarification on identifying performance obligations and the implementation of the licensing guidance. These ASUs are effective for public entities for annual and interim periods beginning after December 15, 2017 . Adoption prior to interim periods beginning after December 15, 2016 is not permitted. The guidance permits two implementation approaches, one requiring retrospective application of the new ASU with restatement of prior years and one requiring prospective application of the new ASU with disclosure of results under old standards. During 2016 , we expect to complete an evaluation of the effects adoption of this ASU may have on our financial position, results of operations and cash flows.

Business Acquisition (Tables)

Business Acquisition (Tables)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Schedule of Purchase Price Allocation	The fair value amounts have been determined using preliminary estimates. A preliminary valuation was completed in July 2016 and we believe it will be finalized by the end of 2016 . The preliminary allocation of the purchase price was as follows (in millions): Purchase Price Allocation Current assets acquired net of liabilities assumed $ 14.0 Property, plant and equipment 4.6 Identifiable intangible assets, excluding IPR&D 105.1 Identifiable IPR&D 5.7 Deferred tax liabilities (39.5 ) Goodwill 85.2 Total $ 175.1
Schedule of Identifiable Intangible Assets	The identifiable intangible assets, excluding IPR&D, include the following (in millions): Fair Value Weighted Average Useful Lives (Yrs) Portfolio of disposables $ 102.9 15 Enteral access technology 2.2 6 Total $ 105.1
Summary of Pro Forma Information	The following unaudited pro forma information is presented in the table below for the three and six months ended June 30, 2016 and 2015 as if the Acquisition had occurred on January 1, 2015 (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net sales $ 404.5 $ 402.6 $ 802.3 $ 809.5 Net income 8.9 8.6 21.6 28.5 Earnings per share: Basic $ 0.19 $ 0.18 $ 0.46 $ 0.61 Diluted 0.19 0.18 0.46 0.61

Supplemental Balance Sheet In21

Supplemental Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable	Accounts receivable consist of the following (in millions): June 30, 2016 December 31, 2015 Accounts receivable $ 196.8 $ 226.3 Allowances and doubtful accounts (1.6 ) (1.6 ) Accounts receivable, net $ 195.2 $ 224.7
Schedule of inventories	Inventories at the lower of cost (determined on the LIFO/FIFO or weighted-average cost methods) or market consist of the following (in millions): June 30, 2016 December 31, 2015 LIFO Non- Total LIFO Non- Total Raw materials $ 51.8 $ 0.8 $ 52.6 $ 49.7 $ 1.1 $ 50.8 Work in process 55.6 0.6 56.2 46.1 0.1 46.2 Finished goods 159.4 40.2 199.6 165.8 46.3 212.1 Supplies and other — 13.3 13.3 0.1 11.6 11.7 266.8 54.9 321.7 261.7 59.1 320.8 Excess of FIFO or weighted-average cost over LIFO cost (11.4 ) — (11.4 ) (17.6 ) — (17.6 ) Total $ 255.4 $ 54.9 $ 310.3 $ 244.1 $ 59.1 $ 303.2
Schedule of property, plant and equipment	Property, plant and equipment consists of the following (in millions): June 30, 2016 December 31, 2015 Land $ 2.2 $ 2.1 Buildings 87.2 86.7 Machinery and equipment 503.1 492.8 Construction in progress 18.0 18.3 610.5 599.9 Less accumulated depreciation (337.9 ) (320.4 ) Total $ 272.6 $ 279.5
Changes in the carrying amount of goodwill by business segment	The changes in the carrying amount of goodwill by business segment are as follows (in millions): S&IP Medical Devices Consolidated Goodwill Accumulated Impairment Goodwill, net Goodwill Accumulated Impairment Goodwill, net Goodwill, net Balance at December 31, 2015 $ 740.8 $ (474.0 ) $ 266.8 $ 678.4 $ — $ 678.4 $ 945.2 Goodwill acquired — — — 85.2 — 85.2 85.2 Currency translation adjustment 0.2 — 0.2 1.0 — 1.0 1.2 Balance at June 30, 2016 $ 741.0 $ (474.0 ) $ 267.0 $ 764.6 $ — $ 764.6 $ 1,031.6
Schedule of intangible assets subject to amortization	Intangible assets subject to amortization consist of the following (in millions): June 30, 2016 December 31, 2015 Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Trademarks $ 126.5 $ (92.2 ) $ 34.3 $ 126.6 $ (90.3 ) $ 36.3 Patents and acquired technologies 253.9 (124.5 ) 129.4 149.1 (117.3 ) 31.8 Other 55.5 (42.5 ) 13.0 55.1 (40.6 ) 14.5 Total $ 435.9 $ (259.2 ) $ 176.7 $ 330.8 $ (248.2 ) $ 82.6
Schedule of estimated amortization expense	We estimate amortization expense for the remainder of 2016 and the following four years and beyond will be as follows (in millions): For the years ending December 31, 2016 $ 11.4 2017 21.4 2018 19.2 2019 15.4 2020 13.1 Thereafter 96.2 Total $ 176.7
Schedule of accrued expenses	Accrued expenses consist of the following (in millions): June 30, 2016 December 31, 2015 Accrued rebates $ 56.0 $ 73.9 Accrued salaries and wages 43.8 34.5 Accrued taxes - income and other 9.1 15.3 Other 27.4 28.3 Total $ 136.3 $ 152.0
Schedule of other long-term liabilities	Other long-term liabilities consist of the following (in millions): June 30, 2016 December 31, 2015 Taxes payable $ 3.0 $ 1.3 Accrued compensation benefits 9.8 9.5 Other 17.4 17.0 Total $ 30.2 $ 27.8

Fair Value Information (Tables)

Fair Value Information (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of fair value of financial instruments	The following table includes the fair value of our financial instruments for which disclosure of fair value is required (in millions): June 30, 2016 December 31, 2015 Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Assets Cash and cash equivalents 1 $ 79.2 $ 79.2 $ 129.5 $ 129.5 Liabilities Senior Unsecured Notes, net of Unamortized Discount 1 246.2 244.1 245.9 252.5 Senior Secured Term Loan, net of Unamortized Discount 2 332.8 339.2 332.2 337.3

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Schedule of debt balances	As of June 30, 2016 and December 31, 2015 , our debt balances were as follows (in millions): Weighted-Average Interest Rate Maturities June 30, 2016 December 31, 2015 Revolving Credit Facility 2.74 % 2019 $ 45.0 $ — Senior Secured Term Loan 4.00 % 2021 339.0 339.0 Senior Unsecured Notes 6.25 % 2022 250.0 250.0 Unamortized Debt Discounts and Issuance Costs: Senior Secured Term Loan (6.2 ) (6.8 ) Senior Unsecured Notes (3.8 ) (4.1 ) Total Debt $ 624.0 $ 578.1

Accumulated Other Comprehensi24

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Schedule of changes in the components of Accumulated Other Comprehensive Income, Net of Tax	The changes in the components of Accumulated Other Comprehensive Income (“AOCI”), net of tax, are as follows (in millions): Unrealized Translation Cash Flow Hedges Defined Benefit Pension Plans Accumulated Other Comprehensive Income Balance, December 31, 2015 $ (40.4 ) $ (1.2 ) $ (1.6 ) $ (43.2 ) Other comprehensive income 3.5 1.5 0.1 5.1 Balance, June 30, 2016 $ (36.9 ) $ 0.3 $ (1.5 ) $ (38.1 ) The changes in the components of AOCI, including the tax effect, are as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Unrealized translation $ (2.0 ) $ (3.0 ) $ 3.5 $ (9.8 ) Defined benefit pension plans 0.1 0.1 0.1 0.1 Tax effect — 0.1 — 0.1 Defined benefit pension plans, net of tax 0.1 0.2 0.1 0.2 Cash flow hedges 0.4 (0.8 ) 1.9 (0.3 ) Tax effect — 0.3 (0.4 ) 0.1 Cash flow hedges, net of tax 0.4 (0.5 ) 1.5 (0.2 ) Change in AOCI $ (1.5 ) $ (3.3 ) $ 5.1 $ (9.8 )

Earnings Per Share ("EPS") (Tab

Earnings Per Share ("EPS") (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Calculation of basic and diluted earnings per share	The calculation of basic and diluted earnings per share for the three and six months ended June 30, 2016 and 2015 is set forth in the following table (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net income $ 6.5 $ 8.0 $ 20.7 $ 29.7 Weighted Average Shares Outstanding: Basic weighted average shares outstanding 46.7 46.6 46.6 46.6 Dilutive effect of stock options and restricted share unit awards 0.2 0.2 0.2 0.2 Diluted weighted average shares outstanding 46.9 46.8 46.8 46.8 Earnings Per Share Basic $ 0.14 $ 0.17 $ 0.44 $ 0.64 Diluted $ 0.14 $ 0.17 $ 0.44 $ 0.63

Business Segment Information (T

Business Segment Information (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Information concerning unaudited consolidated operations by business segment	Information concerning unaudited consolidated operations by business segment is presented in the following table (in millions): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net Sales S&IP $ 256.7 $ 255.3 $ 511.4 $ 510.1 Medical Devices 141.5 126.9 268.2 249.2 Corporate and Other 1.8 7.1 5.2 24.2 Total Net Sales 400.0 389.3 784.8 783.5 Operating Profit S&IP 25.1 25.5 49.7 45.0 Medical Devices 29.0 33.3 58.7 58.1 Corporate and Other (a) (30.8 ) (36.0 ) (50.1 ) (51.4 ) Other (expense) and income, net (b) (5.7 ) (0.7 ) (7.6 ) 11.3 Total Operating Profit 17.6 22.1 50.7 63.0 Interest income 0.1 0.1 0.3 0.2 Interest expense (8.3 ) (8.9 ) (16.3 ) (17.2 ) Income before Income Taxes $ 9.4 $ 13.3 $ 34.7 $ 46.0 ______________________________ (a) Corporate and Other for the three and six months ended June 30, 2016 includes $17 million and $32 million , respectively, of general expenses, $2 million and $5 million , respectively, of post spin-related transition expenses, $9 million and $10 million , respectively, of acquisition, integration and restructuring expenses related to the Acquisition (See Note 2 , “Business Acquisition”) and $2 million and $3 million , respectively of costs related to corporate sales. Corporate and Other for the three and six months ended June 30, 2015 includes $13 million and $22 million , respectively, of general expenses and $20 million and $30 million , respectively, of post spin-related transition expenses and $4 million of costs and $2 million of profit, respectively, from corporate sales. (b) Other expense includes amounts incurred related to litigation matters. See Note 8 , “Commitments and Contingencies.”

Supplemental Guarantor Financ27

Supplemental Guarantor Financial Information (Tables)	6 Months Ended
	Jun. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Income Statement and Comprehensive Income Statements	HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Three Months Ended June 30, 2016 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 372.3 $ 110.8 $ (83.1 ) $ 400.0 Cost of products sold — 247.7 94.7 (83.1 ) 259.3 Gross Profit — 124.6 16.1 — 140.7 Research and development — 9.5 — — 9.5 Selling and general expenses 11.1 81.5 15.3 — 107.9 Other (income) and expense, net (0.3 ) 12.1 (6.1 ) — 5.7 Operating (Loss) Profit (10.8 ) 21.5 6.9 — 17.6 Interest income 0.1 — 0.7 (0.7 ) 0.1 Interest expense (8.4 ) (0.6 ) — 0.7 (8.3 ) (Loss) Income Before Income Taxes (19.1 ) 20.9 7.6 — 9.4 Income tax benefit (provision) 7.2 (8.7 ) (1.4 ) — (2.9 ) Equity in earnings of consolidated subsidiaries 18.4 7.7 — (26.1 ) — Net Income 6.5 19.9 6.2 (26.1 ) 6.5 Total other comprehensive loss, net of tax (1.5 ) (0.5 ) (2.9 ) 3.4 (1.5 ) Comprehensive Income $ 5.0 $ 19.4 $ 3.3 $ (22.7 ) $ 5.0 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Six Months Ended June 30, 2016 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 723.5 $ 213.6 $ (152.3 ) $ 784.8 Cost of products sold — 479.9 180.0 (152.3 ) 507.6 Gross Profit — 243.6 33.6 — 277.2 Research and development — 18.2 — — 18.2 Selling and general expenses 20.7 150.8 29.2 — 200.7 Other (income) and expense, net (0.4 ) 20.0 (12.0 ) — 7.6 Operating (Loss) Profit (20.3 ) 54.6 16.4 — 50.7 Interest income 0.2 — 1.3 (1.2 ) 0.3 Interest expense (16.5 ) (1.0 ) — 1.2 (16.3 ) (Loss) Income Before Income Taxes (36.6 ) 53.6 17.7 — 34.7 Income tax benefit (provision) 13.8 (20.0 ) (7.8 ) — (14.0 ) Equity in earnings of consolidated subsidiaries 43.5 12.4 — (55.9 ) — Net Income 20.7 46.0 9.9 (55.9 ) 20.7 Total other comprehensive income, net of tax 5.1 4.5 2.7 (7.2 ) 5.1 Comprehensive Income $ 25.8 $ 50.5 $ 12.6 $ (63.1 ) $ 25.8 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Three Months Ended June 30, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 364.6 $ 113.5 $ (88.8 ) $ 389.3 Cost of products sold — 247.0 96.2 (88.8 ) 254.4 Gross Profit — 117.6 17.3 — 134.9 Research and development — 6.3 — — 6.3 Selling and general expenses 9.1 81.1 15.6 — 105.8 Other (income) and expense, net (0.2 ) 2.5 (1.6 ) — 0.7 Operating (Loss) Profit (8.9 ) 27.7 3.3 — 22.1 Interest income 0.3 — 1.7 (1.9 ) 0.1 Interest expense (10.0 ) (0.7 ) (0.1 ) 1.9 (8.9 ) (Loss) Income Before Income Taxes (18.6 ) 27.0 4.9 — 13.3 Income tax benefit (provision) 13.4 (18.7 ) — — (5.3 ) Equity in earnings of consolidated subsidiaries 13.2 2.9 — (16.1 ) — Net Income 8.0 11.2 4.9 (16.1 ) 8.0 Total other comprehensive loss, net of tax — (0.2 ) (3.1 ) — (3.3 ) Comprehensive Income $ 8.0 $ 11.0 $ 1.8 $ (16.1 ) $ 4.7 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions) Six Months Ended June 30, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net Sales $ — $ 724.9 $ 227.2 $ (168.6 ) $ 783.5 Cost of products sold — 490.6 194.5 (168.6 ) 516.5 Gross Profit — 234.3 32.7 — 267.0 Research and development — 12.3 — — 12.3 Selling and general expenses 18.2 154.3 30.5 — 203.0 Other (income) and expense, net (0.4 ) 4.8 (15.7 ) — (11.3 ) Operating (Loss) Profit (17.8 ) 62.9 17.9 — 63.0 Interest income 0.3 — 1.8 (1.9 ) 0.2 Interest expense (17.8 ) (1.0 ) (0.3 ) 1.9 (17.2 ) (Loss) Income Before Income Taxes (35.3 ) 61.9 19.4 — 46.0 Income tax benefit (provision) 13.4 (24.2 ) (5.5 ) — (16.3 ) Equity in earnings of consolidated subsidiaries 51.6 16.1 — (67.7 ) — Net Income 29.7 53.8 13.9 (67.7 ) 29.7 Total other comprehensive loss, net of tax — (0.3 ) (9.5 ) — (9.8 ) Comprehensive Income $ 29.7 $ 53.5 $ 4.4 $ (67.7 ) $ 19.9
Condensed Consolidating Balance Sheets	HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions) As of December 31, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Current Assets Cash and cash equivalents $ 92.3 $ — $ 39.7 $ (2.5 ) $ 129.5 Accounts receivable, net 3.0 440.8 221.7 (440.8 ) 224.7 Inventories — 258.4 44.8 — 303.2 Prepaid and other current assets 5.0 10.8 3.0 (0.2 ) 18.6 Total Current Assets 100.3 710.0 309.2 (443.5 ) 676.0 Property, Plant and Equipment, net — 228.7 50.8 — 279.5 Investment in Consolidated Subsidiaries 1,750.8 277.7 — (2,028.5 ) — Goodwill — 918.6 26.6 — 945.2 Other Intangible Assets, net — 82.6 — — 82.6 Other Assets 1.4 0.3 15.2 — 16.9 TOTAL ASSETS $ 1,852.5 $ 2,217.9 $ 401.8 $ (2,472.0 ) $ 2,000.2 LIABILITIES AND EQUITY Current Liabilities Trade accounts payable $ 251.4 $ 309.4 $ 42.7 $ (440.3 ) $ 163.2 Accrued expenses 6.6 115.4 33.4 (3.4 ) 152.0 Total Current Liabilities 258.0 424.8 76.1 (443.7 ) 315.2 Long-Term Debt 578.1 — — — 578.1 Other Long-Term Liabilities 1.8 41.6 8.2 — 51.6 Total Liabilities 837.9 466.4 84.3 (443.7 ) 944.9 Total Equity 1,014.6 1,751.5 317.5 (2,028.3 ) 1,055.3 TOTAL LIABILITIES AND EQUITY $ 1,852.5 $ 2,217.9 $ 401.8 $ (2,472.0 ) $ 2,000.2 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions) As of June 30, 2016 Parent Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current Assets Cash and cash equivalents $ 16.6 $ 9.3 $ 53.3 $ — $ 79.2 Accounts receivable, net 3.4 490.9 223.7 (522.8 ) 195.2 Inventories — 273.1 37.2 — 310.3 Prepaid and other current assets 5.5 17.4 2.8 (0.7 ) 25.0 Total Current Assets 25.5 790.7 317.0 (523.5 ) 609.7 Property, Plant and Equipment, net — 225.3 47.3 — 272.6 Investment in Consolidated Subsidiaries 2,032.1 285.5 — (2,317.6 ) — Goodwill — 1,003.7 27.9 — 1,031.6 Other Intangible Assets, net — 182.4 — — 182.4 Other Assets 1.2 2.4 12.1 — 15.7 TOTAL ASSETS $ 2,058.8 $ 2,490.0 $ 404.3 $ (2,841.1 ) $ 2,112.0 LIABILITIES AND EQUITY Current Liabilities Trade accounts payable $ 335.1 $ 311.2 $ 41.0 $ (518.7 ) $ 168.6 Accrued expenses 8.4 106.2 26.4 (4.7 ) 136.3 Total Current Liabilities 343.5 417.4 67.4 (523.4 ) 304.9 Long-Term Debt 624.0 — — — 624.0 Other Long-Term Liabilities 1.8 83.7 8.1 — 93.6 Total Liabilities 969.3 501.1 75.5 (523.4 ) 1,022.5 Total Equity 1,089.5 1,988.9 328.8 (2,317.7 ) 1,089.5 TOTAL LIABILITIES AND EQUITY $ 2,058.8 $ 2,490.0 $ 404.3 $ (2,841.1 ) $ 2,112.0
Condensed Consolidating Statements of Cash Flows	HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions) Six Months Ended June 30, 2016 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Cash (Used in) Provided by Operating Activities $ (7.5 ) $ 85.5 $ 16.0 $ — $ 94.0 Investing Activities Capital expenditures — (11.6 ) (2.5 ) — (14.1 ) Acquisition of business, net of cash acquired (175.1 ) — — — (175.1 ) Intercompany contributions 0.5 (65.0 ) 1.8 62.7 — Cash Used in Investing Activities (174.6 ) (76.6 ) (0.7 ) 62.7 (189.2 ) Financing Activities Intercompany contributions 62.3 — (2.1 ) (60.2 ) — Line of credit facility proceeds 72.0 — — — 72.0 Line of credit facility repayments (27.0 ) — — — (27.0 ) Purchase of treasury stock (0.9 ) — — — (0.9 ) Cash Provided by (Used in) Financing Activities 106.4 — (2.1 ) (60.2 ) 44.1 Effect of Exchange Rate on Cash and Cash Equivalents — 0.4 0.4 — 0.8 (Decrease) Increase in Cash and Cash Equivalents (75.7 ) 9.3 13.6 2.5 (50.3 ) Cash and Cash Equivalents, Beginning of Period 92.3 — 39.7 (2.5 ) 129.5 Cash and Cash Equivalents, End of Period $ 16.6 $ 9.3 $ 53.3 $ — $ 79.2 HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions) Six Months Ended June 30, 2015 Parent Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Cash (Used in) Provided by Operating Activities $ (18.9 ) $ 22.4 $ 52.2 $ — $ 55.7 Investing Activities Capital expenditures — (39.1 ) (6.1 ) — (45.2 ) Proceeds from property dispositions — — 7.7 — 7.7 Cash (Used in) Provided by Investing Activities — (39.1 ) 1.6 — (37.5 ) Financing Activities Intercompany contributions 62.4 13.2 (75.6 ) — — Debt repayments (51.0 ) — — — (51.0 ) Purchase of treasury stock (1.0 ) — — — (1.0 ) Proceeds from the exercise of stock options 0.9 — — — 0.9 Cash Provided by (Used in) Financing Activities 11.3 13.2 (75.6 ) — (51.1 ) Effect of Exchange Rate on Cash and Cash Equivalents — (0.1 ) (1.7 ) — (1.8 ) Decrease in Cash and Cash Equivalents (7.6 ) (3.6 ) (23.5 ) — (34.7 ) Cash and Cash Equivalents, Beginning of Period 101.2 3.9 43.9 — 149.0 Cash and Cash Equivalents, End of Period $ 93.6 $ 0.3 $ 20.4 $ — $ 114.3

Accounting Policies - Addition

Accounting Policies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2016segment
Accounting Policies [Abstract]
Number of business segments	2
Term of lease contract (more than)	12 months

Business Acquisition (Details)

Business Acquisition (Details) - USD ($) $ in Millions	May 02, 2016	Jun. 30, 2016	Jun. 30, 2016
Business Acquisition [Line Items]
Revenue of acquiree		$ 9	$ 9
Restructuring Reserve		3	3
Medsystems Holdings, Inc.
Business Acquisition [Line Items]
Consideration transferred	$ 175
Restructuring Charges		$ 9	$ 10

Business Acquisition - Purchas

Business Acquisition - Purchase Price Allocation (Details) - USD ($) $ in Millions	Jun. 30, 2016	May 02, 2016	Dec. 31, 2015
Acquired Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 1,031.6		$ 945.2
Medsystems Holdings, Inc.
Acquired Indefinite-lived Intangible Assets [Line Items]
Current assets acquired net of liabilities assumed		$ 14
Property, plant and equipment		4.6
Identifiable intangible assets, excluding IPR&D		105.1
Deferred tax liabilities		(39.5)
Goodwill		85.2
Total		175.1
Medsystems Holdings, Inc. | Identifiable IPR&D
Acquired Indefinite-lived Intangible Assets [Line Items]
Identifiable IPR&D		$ 5.7

Business Acquisition - Schedul

Business Acquisition - Schedule of Acquired Finite-Lived Intangible Assets (Details) - Medsystems Holdings, Inc. $ in Millions	May 02, 2016USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 105.1
Portfolio of disposables
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 102.9
Weighted Average Useful Lives (Yrs)	15 years
Enteral access technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 2.2
Weighted Average Useful Lives (Yrs)	6 years

Business Acquisition - Pro For

Business Acquisition - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Business Combinations [Abstract]
Net sales	$ 404.5	$ 402.6	$ 802.3	$ 809.5
Net income	$ 8.9	$ 8.6	$ 21.6	$ 28.5
Basic (in dollars per share)	$ 0.19	$ 0.18	$ 0.46	$ 0.61
Diluted (in dollars per share)	$ 0.19	$ 0.18	$ 0.46	$ 0.61

Supplemental Balance Sheet In33

Supplemental Balance Sheet Information - Accounts Receivable (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 196.8	$ 226.3
Allowances and doubtful accounts	(1.6)	(1.6)
Accounts receivable, net	$ 195.2	$ 224.7

Supplemental Balance Sheet In34

Supplemental Balance Sheet Information - Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Inventory, LIFO, Net [Abstract]
Raw materials	$ 51.8	$ 49.7
Work in process	55.6	46.1
Finished goods	159.4	165.8
Supplies and other	0	0.1
Inventory, gross	266.8	261.7
Excess of FIFO or weighted-average cost over LIFO cost	(11.4)	(17.6)
Inventories, net	255.4	244.1
Inventory, Non-LIFO, Net [Abstract]
Raw materials	0.8	1.1
Work in process	0.6	0.1
Finished goods	40.2	46.3
Supplies and other	13.3	11.6
Inventory, gross	54.9	59.1
Inventories, net	54.9	59.1
Inventory, Net [Abstract]
Raw materials	52.6	50.8
Work in process	56.2	46.2
Finished goods	199.6	212.1
Supplies and other	13.3	11.7
Inventory, gross	321.7	320.8
Excess of FIFO or weighted-average cost over LIFO cost	(11.4)	(17.6)
Inventories, net	$ 310.3	$ 303.2

Supplemental Balance Sheet In35

Supplemental Balance Sheet Information - Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 610.5		$ 610.5		$ 599.9
Less accumulated depreciation	(337.9)		(337.9)		(320.4)
Total	272.6		272.6		279.5
Depreciation expense	11	$ 9	21	$ 19
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2.2		2.2		2.1
Buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	87.2		87.2		86.7
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	503.1		503.1		492.8
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 18		$ 18		$ 18.3

Supplemental Balance Sheet In36

Supplemental Balance Sheet Information - Schedule of Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)
Goodwill [Roll Forward]
Balance at December 31, 2015, Goodwill, net	$ 945.2
Goodwill acquired	85.2
Currency translation adjustment	1.2
Balance at June 30, 2016, Goodwill, net	1,031.6
S&IP
Goodwill [Roll Forward]
Balance at December 31, 2015, Goodwill, gross	740.8
Balance at December 31, 2015, Accumulated Impairment	(474)
Balance at December 31, 2015, Goodwill, net	266.8
Goodwill acquired	0
Currency translation adjustment	0.2
Balance at June 30, 2016, Goodwill, gross	741
Balance at June 30, 2016, Accumulated Impairment	(474)
Balance at June 30, 2016, Goodwill, net	267
Medical Devices
Goodwill [Roll Forward]
Balance at December 31, 2015, Goodwill, gross	678.4
Balance at December 31, 2015, Accumulated Impairment	0
Balance at December 31, 2015, Goodwill, net	678.4
Goodwill acquired	85.2
Currency translation adjustment	1
Balance at June 30, 2016, Goodwill, gross	764.6
Balance at June 30, 2016, Accumulated Impairment	0
Balance at June 30, 2016, Goodwill, net	$ 764.6

Supplemental Balance Sheet In37

Supplemental Balance Sheet Information - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	May 02, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 435.9		$ 435.9			$ 330.8
Accumulated Amortization	(259.2)		(259.2)			(248.2)
Net Carrying Amount	176.7		176.7			82.6
Amortization expense for intangible assets	5	$ 6	11	$ 13
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	126.5		126.5			126.6
Accumulated Amortization	(92.2)		(92.2)			(90.3)
Net Carrying Amount	34.3		34.3			36.3
Patents and acquired technologies
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	253.9		253.9			149.1
Accumulated Amortization	(124.5)		(124.5)			(117.3)
Net Carrying Amount	129.4		129.4			31.8
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	55.5		55.5			55.1
Accumulated Amortization	(42.5)		(42.5)			(40.6)
Net Carrying Amount	$ 13		$ 13			$ 14.5
Identifiable IPR&D | Medsystems Holdings, Inc.
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets acquired					$ 5.7

Supplemental Balance Sheet In38

Supplemental Balance Sheet Information - Schedule of Estimated Amortization Expense (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2,016	$ 11.4
2,017	21.4
2,018	19.2
2,019	15.4
2,020	13.1
Thereafter	96.2
Net Carrying Amount	$ 176.7	$ 82.6

Supplemental Balance Sheet In39

Supplemental Balance Sheet Information - Accrued Expenses (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued rebates	$ 56	$ 73.9
Accrued salaries and wages	43.8	34.5
Accrued taxes - income and other	9.1	15.3
Other	27.4	28.3
Total	$ 136.3	$ 152

Supplemental Balance Sheet In40

Supplemental Balance Sheet Information - Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Taxes payable	$ 3	$ 1.3
Accrued compensation benefits	9.8	9.5
Other	17.4	17
Total	$ 30.2	$ 27.8

Fair Value Information - Addit

Fair Value Information - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Inputs, Level 1 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 79.2	$ 129.5
Fair Value, Inputs, Level 1 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	79.2	129.5
Senior Unsecured Notes | 6.25% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	250	250
Senior Unsecured Notes | 6.25% Senior Notes | Fair Value, Inputs, Level 1 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	246.2	245.9
Senior Unsecured Notes | 6.25% Senior Notes | Fair Value, Inputs, Level 1 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	244.1	252.5
Senior Secured Term Loan | Term loan facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	339	339
Senior Secured Term Loan | Term loan facility | Fair Value, Inputs, Level 2 | Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	332.8	332.2
Senior Secured Term Loan | Term loan facility | Fair Value, Inputs, Level 2 | Estimated Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	339.2	337.3
Foreign exchange contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets		0
Foreign exchange contracts | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	1	2
Derivative assets	$ 1	$ 0

Debt - Schedule of Debt (Detai

Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total Debt	$ 624	$ 578.1
Revolving Credit Facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)	2.74%
Revolving Credit Facility	$ 45	$ 0
Senior Secured Term Loan | Revolving Credit Facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)		2.74%
Senior Secured Term Loan | Term loan facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)	4.00%	4.00%
Long-term debt	$ 339	$ 339
Unamortized Debt Discounts and Issuance Costs	$ (6.2)	$ (6.8)
Senior Unsecured Notes | 6.25% Senior Notes
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)	6.25%	6.25%
Long-term debt	$ 250	$ 250
Unamortized Debt Discounts and Issuance Costs	$ (3.8)	$ (4.1)

Debt - Additional Information

Debt - Additional Information (Details) - USD ($)	May 02, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Line of credit facility proceeds	$ 72,000,000		$ 72,000,000	$ 0
Repayments of Lines of Credit			$ 27,000,000	$ 0
Senior Secured Term Loan | Term loan facility
Debt Instrument [Line Items]
Effective interest rate (as a percent)		4.00%	4.00%
Senior Unsecured Notes | 6.25% Senior Notes
Debt Instrument [Line Items]
Weighted-average interest rate (as a percent)		6.25%	6.25%		6.25%
Revolving Credit Facility
Debt Instrument [Line Items]
Revolving Credit Facility		$ 45,000,000	$ 45,000,000		$ 0
Weighted-average interest rate (as a percent)		2.74%	2.74%
Revolving Credit Facility | Credit Facility
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage		0.40%
Consolidated total leverage ratio		2.25	2.25
Revolving Credit Facility | Credit Facility | Leverage Ratio, Less than 2.25
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage		0.25%
Revolving Credit Facility | Credit Facility | Base rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		0.75%
Revolving Credit Facility | Credit Facility | Base rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.50%
Revolving Credit Facility | Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.75%
Revolving Credit Facility | Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		2.50%
Revolving Credit Facility | Secured line of credit | Credit Facility
Debt Instrument [Line Items]
Term of credit facility (in years)			5 years
Borrowing capacity		$ 250,000,000	$ 250,000,000
Revolving Credit Facility | Senior Secured Term Loan
Debt Instrument [Line Items]
Effective interest rate (as a percent)		2.72%	2.72%
Weighted-average interest rate (as a percent)					2.74%
Revolving Credit Facility | Senior Secured Term Loan | Credit Facility
Debt Instrument [Line Items]
Amount available for borrowing		$ 202,000,000	$ 202,000,000
Revolving Credit Facility | Senior Secured Term Loan | Term loan facility | Base rate | Scenario 1
Debt Instrument [Line Items]
Interest rate floor (as a percent)			0.75%
Revolving Credit Facility | Senior Secured Term Loan | Term loan facility | Base rate | Scenario 3
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)			2.25%
Revolving Credit Facility | Senior Secured Term Loan | Term loan facility | LIBOR | Scenario 1
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)			3.25%
Revolving Credit Facility | Senior Secured Term Loan | Term loan facility | U.S. federal funds effective rate | Scenario 2
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)			0.50%
Revolving Credit Facility | Senior Secured Term Loan | Term loan facility | One month LIBOR Rate | Scenario 3
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)			1.00%
Letter of credit | Secured line of credit | Credit Facility
Debt Instrument [Line Items]
Borrowing capacity		75,000,000	$ 75,000,000
Letter of credit | Senior Secured Term Loan | Credit Facility
Debt Instrument [Line Items]
Amount outstanding		3,000,000	3,000,000
Swingline sub-facility | Secured line of credit | Credit Facility
Debt Instrument [Line Items]
Borrowing capacity		$ 25,000,000	$ 25,000,000

Accumulated Other Comprehensi44

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015			$ 1,055.3
Other comprehensive income	$ (1.5)	$ (3.3)	5.1	$ (9.8)
Balance, June 30, 2016	1,089.5		1,089.5
Total Other Comprehensive (Loss) Income, Net of Tax	(1.5)	(3.3)	5.1	(9.8)
Unrealized Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015			(40.4)
Other comprehensive income			3.5
Balance, June 30, 2016	(36.9)		(36.9)
Unrealized translation	(2)	(3)	3.5	(9.8)
Total Other Comprehensive (Loss) Income, Net of Tax			3.5
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015			(1.2)
Other comprehensive income			1.5
Balance, June 30, 2016	0.3		0.3
Cash flow hedges	0.4	(0.8)	1.9	(0.3)
Tax effect	0	0.3	(0.4)	0.1
Cash flow hedges, net of tax	0.4	(0.5)	1.5	(0.2)
Total Other Comprehensive (Loss) Income, Net of Tax			1.5
Defined Benefit Pension Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015			(1.6)
Other comprehensive income			0.1
Balance, June 30, 2016	(1.5)		(1.5)
Defined benefit pension plans	0.1	0.1	0.1	0.1
Tax effect	0	0.1	0	0.1
Defined benefit pension plans, net of tax	0.1	$ 0.2	0.1	$ 0.2
Total Other Comprehensive (Loss) Income, Net of Tax			0.1
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015			(43.2)
Other comprehensive income			5.1
Balance, June 30, 2016	$ (38.1)		(38.1)
Total Other Comprehensive (Loss) Income, Net of Tax			$ 5.1

Stock-Based Compensation - Add

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 6	$ 6	$ 9	$ 11
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	2	3	3	4
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1	$ 3	4	$ 7
TSR units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 2		$ 2
Restricted share units, grants in period (in shares)			230
Vesting period			3 years
Expected volatility rate	25.00%		25.00%
Weighted average grant date fair value, grants in period (in dollars per share)	$ 38.64		$ 38.64

Commitments and Contingencies

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal expense and settlement accrual	$ 6	$ 10

Derivative Financial Instrume47

Derivative Financial Instruments - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Derivative [Line Items]
Amounts to be reclassified into net income in next twelve months			$ 0
Gains (losses) on designated hedging instruments	$ 0	$ 0	0	$ 0
Designated hedge ineffectiveness	0	0	0	0
Amounts reclassified form accumulated other comprehensive income	0	0	0	0
Gains (losses) on undesignated hedging instruments	0	$ 0	0	$ 0
Foreign exchange contracts
Derivative [Line Items]
Derivative assets					$ 0
Foreign exchange contracts | Undesignated Hedging instruments
Derivative [Line Items]
Aggregate notional amount	3,700,000		3,700,000
Foreign exchange contracts | Cash flow hedges | Designated as Hedging Instrument
Derivative [Line Items]
Aggregate notional amount	36,000,000		36,000,000
Fair Value, Inputs, Level 2 | Foreign exchange contracts
Derivative [Line Items]
Derivative liabilities	1,000,000		1,000,000		2,000,000
Derivative assets	$ 1,000,000		$ 1,000,000		$ 0

Earnings Per Share ("EPS") - A

Earnings Per Share ("EPS") - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Abstract]
Net income	$ 6.5	$ 8	$ 20.7	$ 29.7
Weighted Average Shares Outstanding:
Basic weighted average shares outstanding (in shares)	46.7	46.6	46.6	46.6
Dilutive effect of stock options and restricted share unit awards (in shares)	0.2	0.2	0.2	0.2
Diluted weighted average shares outstanding (in shares)	46.9	46.8	46.8	46.8
Earnings Per Share
Basic (in dollars per share)	$ 0.14	$ 0.17	$ 0.44	$ 0.64
Diluted (in dollars per share)	$ 0.14	$ 0.17	$ 0.44	$ 0.63
Antidilutive securities excluded from computation of earnings per share (in shares)	1.9		1.9

Business Segment Information -

Business Segment Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Business segment
Net Sales	$ 400	$ 389.3	$ 784.8	$ 783.5
Operating Profit	17.6	22.1	50.7	63
Other (expense) and income, net	(5.7)	(0.7)	(7.6)	11.3
Interest income	0.1	0.1	0.3	0.2
Interest expense	(8.3)	(8.9)	(16.3)	(17.2)
Income Before Income Taxes	9.4	13.3	34.7	46
Selling and general expenses	107.9	105.8	200.7	203
Gross Profit	140.7	134.9	277.2	267
Operating segments | S&IP
Business segment
Net Sales	256.7	255.3	511.4	510.1
Operating Profit	25.1	25.5	49.7	45
Operating segments | Medical Devices
Business segment
Net Sales	141.5	126.9	268.2	249.2
Operating Profit	29	33.3	58.7	58.1
Corporate and Other
Business segment
Net Sales	1.8	7.1	5.2	24.2
Operating Profit	(30.8)	(36)	(50.1)	(51.4)
Selling and general expenses	17	13	32	22
Gross Profit	(2)	(4)	(3)	2
Corporate and Other | Spinoff
Business segment
Restructuring Charges	2	$ 20	5	$ 30
Medsystems Holdings, Inc.
Business segment
Restructuring Charges	9		10
Medsystems Holdings, Inc. | Corporate and Other
Business segment
Restructuring Charges	$ 9		$ 10

Supplemental Guarantor Financ50

Supplemental Guarantor Financial Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Cumulative percentage ownership, after all transactions	100.00%

Supplemental Guarantor Financ51

Supplemental Guarantor Financial Information - Condensed Consolidating Income and Comprehensive Income Statements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Income Statements, Captions [Line Items]
Net Sales	$ 400	$ 389.3	$ 784.8	$ 783.5
Cost of products sold	259.3	254.4	507.6	516.5
Gross Profit	140.7	134.9	277.2	267
Research and development	9.5	6.3	18.2	12.3
Selling and general expenses	107.9	105.8	200.7	203
Other (income) and expense, net	5.7	0.7	7.6	(11.3)
Operating Profit	17.6	22.1	50.7	63
Interest income	0.1	0.1	0.3	0.2
Interest expense	(8.3)	(8.9)	(16.3)	(17.2)
Income Before Income Taxes	9.4	13.3	34.7	46
Income tax benefit (provision)	(2.9)	(5.3)	(14)	(16.3)
Equity in earnings of consolidated subsidiaries	0	0	0	0
Net Income	6.5	8	20.7	29.7
Total other comprehensive loss, net of tax	(1.5)	(3.3)	5.1	(9.8)
Comprehensive Income	5	4.7	25.8	19.9
Eliminations
Condensed Income Statements, Captions [Line Items]
Net Sales	(83.1)	(88.8)	(152.3)	(168.6)
Cost of products sold	(83.1)	(88.8)	(152.3)	(168.6)
Gross Profit	0	0	0	0
Research and development	0	0	0	0
Selling and general expenses	0	0	0	0
Other (income) and expense, net	0	0	0	0
Operating Profit	0	0	0	0
Interest income	(0.7)	(1.9)	(1.2)	(1.9)
Interest expense	0.7	1.9	1.2	1.9
Income Before Income Taxes	0	0	0	0
Income tax benefit (provision)	0	0	0	0
Equity in earnings of consolidated subsidiaries	(26.1)	(16.1)	(55.9)	(67.7)
Net Income	(26.1)	(16.1)	(55.9)	(67.7)
Total other comprehensive loss, net of tax	3.4	0	(7.2)	0
Comprehensive Income	(22.7)	(16.1)	(63.1)	(67.7)
Parent | Reportable Legal Entities
Condensed Income Statements, Captions [Line Items]
Net Sales	0	0	0	0
Cost of products sold	0	0	0	0
Gross Profit	0	0	0	0
Research and development	0	0	0	0
Selling and general expenses	11.1	9.1	20.7	18.2
Other (income) and expense, net	(0.3)	(0.2)	(0.4)	(0.4)
Operating Profit	(10.8)	(8.9)	(20.3)	(17.8)
Interest income	0.1	0.3	0.2	0.3
Interest expense	(8.4)	(10)	(16.5)	(17.8)
Income Before Income Taxes	(19.1)	(18.6)	(36.6)	(35.3)
Income tax benefit (provision)	7.2	13.4	13.8	13.4
Equity in earnings of consolidated subsidiaries	18.4	13.2	43.5	51.6
Net Income	6.5	8	20.7	29.7
Total other comprehensive loss, net of tax	(1.5)	0	5.1	0
Comprehensive Income	5	8	25.8	29.7
Guarantor Subsidiaries | Reportable Legal Entities
Condensed Income Statements, Captions [Line Items]
Net Sales	372.3	364.6	723.5	724.9
Cost of products sold	247.7	247	479.9	490.6
Gross Profit	124.6	117.6	243.6	234.3
Research and development	9.5	6.3	18.2	12.3
Selling and general expenses	81.5	81.1	150.8	154.3
Other (income) and expense, net	12.1	2.5	20	4.8
Operating Profit	21.5	27.7	54.6	62.9
Interest income	0	0	0	0
Interest expense	(0.6)	(0.7)	(1)	(1)
Income Before Income Taxes	20.9	27	53.6	61.9
Income tax benefit (provision)	(8.7)	(18.7)	(20)	(24.2)
Equity in earnings of consolidated subsidiaries	7.7	2.9	12.4	16.1
Net Income	19.9	11.2	46	53.8
Total other comprehensive loss, net of tax	(0.5)	(0.2)	4.5	(0.3)
Comprehensive Income	19.4	11	50.5	53.5
Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Income Statements, Captions [Line Items]
Net Sales	110.8	113.5	213.6	227.2
Cost of products sold	94.7	96.2	180	194.5
Gross Profit	16.1	17.3	33.6	32.7
Research and development	0	0	0	0
Selling and general expenses	15.3	15.6	29.2	30.5
Other (income) and expense, net	(6.1)	(1.6)	(12)	(15.7)
Operating Profit	6.9	3.3	16.4	17.9
Interest income	0.7	1.7	1.3	1.8
Interest expense	0	(0.1)	0	(0.3)
Income Before Income Taxes	7.6	4.9	17.7	19.4
Income tax benefit (provision)	(1.4)	0	(7.8)	(5.5)
Equity in earnings of consolidated subsidiaries	0	0	0	0
Net Income	6.2	4.9	9.9	13.9
Total other comprehensive loss, net of tax	(2.9)	(3.1)	2.7	(9.5)
Comprehensive Income	$ 3.3	$ 1.8	$ 12.6	$ 4.4

Supplemental Guarantor Financ52

Supplemental Guarantor Financial Information - Condensed Consolidating Balance Sheets (Details) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 79.2	$ 129.5	$ 114.3	$ 149
Accounts receivable, net	195.2	224.7
Inventories	310.3	303.2
Prepaid and other current assets	25	18.6
Total Current Assets	609.7	676
Property, Plant and Equipment, net	272.6	279.5
Investment in Consolidated Subsidiaries	0	0
Goodwill	1,031.6	945.2
Other Intangible Assets, net	182.4	82.6
Other Assets	15.7	16.9
TOTAL ASSETS	2,112	2,000.2
Current Liabilities
Trade accounts payable	168.6	163.2
Accrued expenses	136.3	152
Total Current Liabilities	304.9	315.2
Long-Term Debt	624	578.1
Other Long-Term Liabilities	93.6	51.6
Total Liabilities	1,022.5	944.9
Total Equity	1,089.5	1,055.3
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	2,112	2,000.2
Eliminations
Current Assets
Cash and cash equivalents	0	(2.5)	0	0
Accounts receivable, net	(522.8)	(440.8)
Inventories	0	0
Prepaid and other current assets	(0.7)	(0.2)
Total Current Assets	(523.5)	(443.5)
Property, Plant and Equipment, net	0	0
Investment in Consolidated Subsidiaries	(2,317.6)	(2,028.5)
Goodwill	0	0
Other Intangible Assets, net	0	0
Other Assets	0	0
TOTAL ASSETS	(2,841.1)	(2,472)
Current Liabilities
Trade accounts payable	(518.7)	(440.3)
Accrued expenses	(4.7)	(3.4)
Total Current Liabilities	(523.4)	(443.7)
Long-Term Debt	0	0
Other Long-Term Liabilities	0	0
Total Liabilities	(523.4)	(443.7)
Total Equity	(2,317.7)	(2,028.3)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	(2,841.1)	(2,472)
Parent | Reportable Legal Entities
Current Assets
Cash and cash equivalents	16.6	92.3	93.6	101.2
Accounts receivable, net	3.4	3
Inventories	0	0
Prepaid and other current assets	5.5	5
Total Current Assets	25.5	100.3
Property, Plant and Equipment, net	0	0
Investment in Consolidated Subsidiaries	2,032.1	1,750.8
Goodwill	0	0
Other Intangible Assets, net	0	0
Other Assets	1.2	1.4
TOTAL ASSETS	2,058.8	1,852.5
Current Liabilities
Trade accounts payable	335.1	251.4
Accrued expenses	8.4	6.6
Total Current Liabilities	343.5	258
Long-Term Debt	624	578.1
Other Long-Term Liabilities	1.8	1.8
Total Liabilities	969.3	837.9
Total Equity	1,089.5	1,014.6
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	2,058.8	1,852.5
Guarantor Subsidiaries | Reportable Legal Entities
Current Assets
Cash and cash equivalents	9.3	0	0.3	3.9
Accounts receivable, net	490.9	440.8
Inventories	273.1	258.4
Prepaid and other current assets	17.4	10.8
Total Current Assets	790.7	710
Property, Plant and Equipment, net	225.3	228.7
Investment in Consolidated Subsidiaries	285.5	277.7
Goodwill	1,003.7	918.6
Other Intangible Assets, net	182.4	82.6
Other Assets	2.4	0.3
TOTAL ASSETS	2,490	2,217.9
Current Liabilities
Trade accounts payable	311.2	309.4
Accrued expenses	106.2	115.4
Total Current Liabilities	417.4	424.8
Long-Term Debt	0	0
Other Long-Term Liabilities	83.7	41.6
Total Liabilities	501.1	466.4
Total Equity	1,988.9	1,751.5
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	2,490	2,217.9
Non-Guarantor Subsidiaries | Reportable Legal Entities
Current Assets
Cash and cash equivalents	53.3	39.7	$ 20.4	$ 43.9
Accounts receivable, net	223.7	221.7
Inventories	37.2	44.8
Prepaid and other current assets	2.8	3
Total Current Assets	317	309.2
Property, Plant and Equipment, net	47.3	50.8
Investment in Consolidated Subsidiaries	0	0
Goodwill	27.9	26.6
Other Intangible Assets, net	0	0
Other Assets	12.1	15.2
TOTAL ASSETS	404.3	401.8
Current Liabilities
Trade accounts payable	41	42.7
Accrued expenses	26.4	33.4
Total Current Liabilities	67.4	76.1
Long-Term Debt	0	0
Other Long-Term Liabilities	8.1	8.2
Total Liabilities	75.5	84.3
Total Equity	328.8	317.5
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 404.3	$ 401.8

Supplemental Guarantor Financ53

Supplemental Guarantor Financial Information - Condensed Consolidating Statements of Cash Flows (Details) - USD ($) $ in Millions	May 02, 2016	Jun. 30, 2016	Jun. 30, 2015
Operating Activities
Cash (Used in) Provided by Operating Activities		$ 94	$ 55.7
Investing Activities
Capital expenditures		(14.1)	(45.2)
Acquisition of business, net of cash acquired		(175.1)	0
Proceeds from dispositions of property		0	7.7
Intercompany contributions		0
Cash Used in Investing Activities		(189.2)	(37.5)
Financing Activities
Intercompany contributions		0	0
Line of credit facility proceeds	$ 72	72	0
Line of credit facility repayments		(27)	0
Debt repayments		0	(51)
Purchase of treasury stock		(0.9)	(1)
Proceeds from the exercise of stock options		0	0.9
Cash Provided by (Used in) Financing Activities		44.1	(51.1)
Effect of Exchange Rate on Cash and Cash Equivalents		0.8	(1.8)
(Decrease) Increase in Cash and Cash Equivalents		(50.3)	(34.7)
Cash and Cash Equivalents - Beginning of Period		129.5	149
Cash and Cash Equivalents - End of Period		79.2	114.3
Eliminations
Operating Activities
Cash (Used in) Provided by Operating Activities		0	0
Investing Activities
Capital expenditures		0	0
Acquisition of business, net of cash acquired		0
Proceeds from dispositions of property			0
Intercompany contributions		62.7
Cash Used in Investing Activities		62.7	0
Financing Activities
Intercompany contributions		(60.2)	0
Line of credit facility proceeds		0
Line of credit facility repayments		0
Debt repayments			0
Purchase of treasury stock		0	0
Proceeds from the exercise of stock options			0
Cash Provided by (Used in) Financing Activities		(60.2)	0
Effect of Exchange Rate on Cash and Cash Equivalents		0	0
(Decrease) Increase in Cash and Cash Equivalents		2.5	0
Cash and Cash Equivalents - Beginning of Period		(2.5)	0
Cash and Cash Equivalents - End of Period		0	0
Parent | Reportable Legal Entities
Operating Activities
Cash (Used in) Provided by Operating Activities		(7.5)	(18.9)
Investing Activities
Capital expenditures		0	0
Acquisition of business, net of cash acquired		(175.1)
Proceeds from dispositions of property			0
Intercompany contributions		0.5
Cash Used in Investing Activities		(174.6)	0
Financing Activities
Intercompany contributions		62.3	62.4
Line of credit facility proceeds		72
Line of credit facility repayments		(27)
Debt repayments			(51)
Purchase of treasury stock		(0.9)	(1)
Proceeds from the exercise of stock options			0.9
Cash Provided by (Used in) Financing Activities		106.4	11.3
Effect of Exchange Rate on Cash and Cash Equivalents		0	0
(Decrease) Increase in Cash and Cash Equivalents		(75.7)	(7.6)
Cash and Cash Equivalents - Beginning of Period		92.3	101.2
Cash and Cash Equivalents - End of Period		16.6	93.6
Guarantor Subsidiaries | Reportable Legal Entities
Operating Activities
Cash (Used in) Provided by Operating Activities		85.5	22.4
Investing Activities
Capital expenditures		(11.6)	(39.1)
Acquisition of business, net of cash acquired		0
Proceeds from dispositions of property			0
Intercompany contributions		(65)
Cash Used in Investing Activities		(76.6)	(39.1)
Financing Activities
Intercompany contributions		0	13.2
Line of credit facility proceeds		0
Line of credit facility repayments		0
Debt repayments			0
Purchase of treasury stock		0	0
Proceeds from the exercise of stock options			0
Cash Provided by (Used in) Financing Activities		0	13.2
Effect of Exchange Rate on Cash and Cash Equivalents		0.4	(0.1)
(Decrease) Increase in Cash and Cash Equivalents		9.3	(3.6)
Cash and Cash Equivalents - Beginning of Period		0	3.9
Cash and Cash Equivalents - End of Period		9.3	0.3
Non-Guarantor Subsidiaries | Reportable Legal Entities
Operating Activities
Cash (Used in) Provided by Operating Activities		16	52.2
Investing Activities
Capital expenditures		(2.5)	(6.1)
Acquisition of business, net of cash acquired		0
Proceeds from dispositions of property			7.7
Intercompany contributions		1.8
Cash Used in Investing Activities		(0.7)	1.6
Financing Activities
Intercompany contributions		(2.1)	(75.6)
Line of credit facility proceeds		0
Line of credit facility repayments		0
Debt repayments			0
Purchase of treasury stock		0	0
Proceeds from the exercise of stock options			0
Cash Provided by (Used in) Financing Activities		(2.1)	(75.6)
Effect of Exchange Rate on Cash and Cash Equivalents		0.4	(1.7)
(Decrease) Increase in Cash and Cash Equivalents		13.6	(23.5)
Cash and Cash Equivalents - Beginning of Period		39.7	43.9
Cash and Cash Equivalents - End of Period		$ 53.3	$ 20.4